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Introduction 
Adenosine is an endogenous nucleoside and has several proprieties in com-
mon with classical neurotransmitters:  
- it exerts its action via receptors 
- adenosine-producing enzymes are present in synapses 
- its actions can be blocked by specific antagonists 
- its actions are termined by an efficient reuptake system and a me-
tabolising system. 
Adenosine is usually designated as a neuromodulator because there is no 
evidence that it is stored in or released by specific purinergic nerves. 
Adenosine is involved in important biochemical processes, such as energy 
transfer (ATP and ADP) and signal transduction  (cyclic adenosine mono-
phosphate,  cAMP), and it is a building block for some biologically signifi-
cant molecules such as NAD (nicotinamide-adenine-dinucleotide), FAD 
(flavin-adenine-dinucleotide), SAM (S-adenosyl-L-methionine), DNA and 
RNA.  
 
Figure 1. The structure of ATP and derivatives. 
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The endogenous purine nucleoside (Figure 1) is ubiquitous in mammalian 
cell types and, in view of its function in regulating a wide number of 
physio-pathological events (as cytoprotective, anti-inflammatory, CNS neu-
rotransmitters regulator, pain transmission and metabolism modulator 
agent),1-9 a great interest in the understanding of its molecular pharmacol-
ogy and physiology is widely spread in the scientific community.  
Adenosine and ATP have been shown to induce signalling via P1 and P2 
receptors, respectively. P1 (adenosine receptors, ARs) receptors are subdi-
vided into four subtypes, all belonging to the family of cell membrane G 
protein-coupled receptors and named A1, A2A, A2B and A3, which have been 
cloned so far from many mammalian and some non-mammalian species.10-13 
In particular A1 and A3 inhibit, through Gi proteins, adenylyl cyclase activ-
ity, whereas A2A and A2B stimulate, via Gs proteins, this enzyme (see Table 
1). Collectively, these receptors are widespread on virtually every organ 
and tissue and represent promising drug targets for the pharmacological 
intervention in many pathophysiological conditions that are believed to be 
associated with changes of adenosine levels such asthma, neurodegenera-
tives disorders, chronic inflammatory diseases and cancer. 14-15 
 
Table 1. G-protein coupling and signal trasduction mechanism of Adenosine recep-
tor subtypes 
 
 A1 A2A A2B A3 
G-protein Gi/G0 Gs/Golf Gs/Gq/11 Gi/Gq/11 
Signal trasduction ↓cAMP 
↑IP3/DAG 
↑cAMP ↑cAMP 
↑IP3/DAG 
↓cAMP 
↑IP3/DAG 
Affinity for adenosine High High Low Low 
 
It has been suggest that adenosine receptors act as “sensor” and that ex-
tracellular adenosine acts as a “reporter” of metabolic changes in the local 
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tissue environment.16,17 Therefore, under normal conditions adenosine, 
which is continuously produces intracellularly and extracellularly  and 
maintained at low intracellular levels (about 100 nM) by adenosine kinase 
and adenosine deaminase, interacts with the high-affinity A1 and A2A recep-
tor subtypes. In hypoxic, ischemic or inflamed conditions the intracellular 
production of adenosine is increased to very high micromolar concentra-
tions and transported across cell membranes by specific agents finally lead-
ing to the stepwise activation of all four adenosine receptors, including the 
low affinity A2B and A3 subtypes (Table 1).18  
 
 
  
 
Chapter 1 
 
 
The A2B Adenosine Receptor 
 
 
 
Adenosine mediates its effects through activation of a family of four G pro-
tein coupled adenosine receptors (ARs), named A1, A2A, A2B and A3. These 
receptors differs in their affinity for adenosine, in the type of G proteins that 
they recruit, and finally in the downstream signaling pathways that are ac-
tivated in the target cells. Different signal transduction mechanisms have 
been identified for each subtype. In particolar, activation of A2B AR is asso-
ciated with stimlation of adenylate cyclase and activation of phospholipase 
C through the coupling to Gs and Gq/11 proteins, respectively (Figure 2). 
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A2BARs are known as the most poorly characterised of the adenosine P1 
receptors from a pharmacological point of view, since their general low 
affinity toward prototypic ligands exerting specific high affinity and po-
tency in activating each of the remaining AR subtypes. Especially the 
scarceness of medicinal chemistry acquirements about the structural re-
quirements necessary for a potent and selective activation of A2BAR subtype 
has determined a wide-ranging difficulty in detecting the physiological ef-
fects mediated by a direct and selective A2B AR stimulation.
Figure 2. A2B Adenosine Receptor and its signal trasduction mechanism.
Despite these limitations, growing and promising information in the under-
standing of the physiological meaning of these receptors have arisen from 
the exploitation of potency and selectivity of ligands for A1, A2A and/or 
A3ARs employing a strategy of exclusion in model in which more AR sub-
types are co-expressed. The A2A selective agonist CGS 21680 has been re-
ported, for example, as a useful tool for differentiation between A2A and 
A2BARs.19,20 Moreover some potent and selective antagonists of the A2BAR 
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have been employed to distinguish A2B-mediated effects. The characteriza-
tion of A2B receptors, through radioligand binding studies, has been per-
formed, till a few years ago, by using low-affinity and non-selective antago-
nists like [3H]DPCPX, [3H]ZM241385, [125I]ABOPX.21 A helpful advance-
ment in the pharmacological characterization of A2B ARs is supposed to be 
increased by the recent identification of the tritiated form of some new A2B 
antagonists with improved potency and selectivity such as [3H]MRS1754,22 
[3H]OSIP33939123 and [3H]MRE2029F20.24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Chemical structure of non-selective and selective radioligands for bio-
logical assays at Adenosine Receptors. 
 
The contribution of genetic engineering and manipulation (for example gen-
eration of A2BAR knockout mice and transgenic mice over expressing this 
receptor), especially if combined with classical pharmacological investigat-
ions, have determined relevant progress in establishing the therapeutic po-
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tential of A2BARs ligands and, generally, the role of ARs in a variety of 
deseases.25-28  
 
A2B Adenosine Receptors Physiology and Pharmacology 
The A2BAR subtype has been recognized to regulate a wide range of physio-
pathological events. However it results mainly involved in the modulation 
of the cardiovascular functions and in the genesis of inflammation pro-
cesses.  
A role for A2BAR in regulation of vascular tone, cardiac myocyte contrac-
tility, neurosecretion and neurotrasmission, cell growth, gene expression, 
intestinal tone and secretion, and mast cells function has been suggested.19 
Activation of the A2BAR is known to induce angiogenesis,29,30 reduce vascu-
lar permeabilization,31 increase release of inflammatory mediators from hu-
man and canine mast cells29 and modulate neurohypophysial hormone out-
put.32 
Adenosine, through A2B receptors, can exert long-term control over glyco-
gen levels in primary cultures of mouse cortical astrocytes and might there-
fore play a significant role in patho-physiological processes involving long-
term modulation of brain energy metabolism.26 Evidences of a probable 
involvement of A2B adenosine receptors in some tumors growth and devel-
opment have been as well furnished and A2BARs have been proposed as 
targets to control cell growth and proliferation in a human breast cancer cell 
line.33 
ARs play a significant role in regulating ions transport in epithelial tissues 
through a variety of intracellular signalling pathways. Each of the four P1 
receptors has distinctive roles in different epithelial tissue types. The A2B 
receptor has been identified on both the mucosal and basolateral aspect of 
colonic epithelial cells. Activation at either site results in Cl- secretion, via 
The A2B Adenosine Receptor 
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direct activation of the cAMP-activated Cl- channel CFTR (Cystic Fibrosis 
Transmembrane Conductance Regulator).34 An analogous process of adeno-
sine-mediated activation of Cl- secretion has been located at the lung epithe-
lium.35 The stimulated secretory response has been identified to be the result 
of A2B receptor activation and was lost in a cell line derived from a cystic 
fibrosis patient with a defect in ion transport at CFTR, implicating this ion 
channel as the one responsible for the A2B-mediated Cl- secretion.36 
 
Therapeutic potential of A2B adenosine receptor antagonists 
There are growing findings supporting that adenosine plays a role in asthma 
and chronic obstructive pulmonary disease (COPD),37 moreover adenosine 
stimulates production of IL-4 and IL-13 in mast cells via A2B AR activa-
tion.38 Treatment of asthma with selective A2B adenosine receptor antago-
nists has been, so far, one of the most significant therapeutic ambition 
among ARs ligands.39-43 
A2BAR antagonists are directed toward clinical use for treating diabetes 
since these seem to antagonize the adenosine-induced hepatic glucose pro-
duction determining reduction of blood glucose levels after oral administra-
tion.44 A2BAR has been likewise reported to be involved in stimulation of 
proliferation, differentiation and migration of retinal endothelial cells, thus 
A2B antagonists may offer a way to inhibit retinal angiogenesis providing a 
novel therapeutic approach for treatment of diseases associated with aber-
rant neovascularization, such as diabetic retinopathy.45 
The opioid and adenosine systems seem to cooperate to some extent in the 
modulation of pain signalling, in particular, a participation of A2B receptors 
in the analgesic effects mediated by caffeine in an acute animal model of 
nociception (hot plate test) has been documented.46 These findings sup-
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ported the potential therapeutic employment of specific A2B antagonists as 
valuable adjuvant drugs for opioid analgesia with minimal side effects.  
The purinergic regulation of epithelial transports and, above all, the in-
volvement of the A2BAR subtype in determining secretion stimulation, sug-
gest the possibility to employ A2B specific ligands as potential modulators of 
the ions transport and the parallel flux of water which can be considered a 
natural defense system working to “wash away” injuries in the setting of 
cellular damage or inflammation. Selective A2BAR ligands are under inves-
tigation for the treatment of diarrhea and cystic fibrosis.47-49 
 
A2B adenosine receptor and asthma: Clinical development and patents 
Asthma is a chronic inflammatory disease of the airway that involves many 
inflammatory and structural cell types such as mast cells, eosinophils, baso-
phils and lymphocytes. Activation of this cells result in the release of vari-
ous inflammatory mediators that contribute to the typical pathopysiological 
processes that lead to the manifestation of asthma.50 Mast cells, in particular, 
play an essential role in this system.50,51 These cells possess high-affinity 
IgE receptors (FceRI) on their surface, and in the acute phase of the disease, 
the cross linking of mast cell-bound IgE by allergians induces their activa-
tion and degranulation, whereby they release proinflammatory, plasma exu-
dation and mucus hypersecretion. In the chronic phase of asthma, mast cell 
also secrete a wide array  of cytokines  and growth factors including IL-1, 
IL-2, IL-3, IL-4, IL-5, IL-8, IL-9, IL-13, IFN-γ, TNF-α and GM-CSF.52 
These secretions contribute to the chronic inflammatory changes that take 
place, including fibrosis, hypertrophy and hyperplasia of mucus-secreting 
cells and angiogenesis. Such changes may be irreversible, leading to perma-
nent narrowing of the airways.53 
The A2B Adenosine Receptor 
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There is much evidence to suggest that adenosine plays a central role in the 
asthmatic process being the activation of mast cells a key element.54 In hu-
man lung mast cells, adenosine was shown to potentiate mediator release.55 
Similary in bronchoalveolar fluid (BALF) cells obtained from asthmatic 
patients after allergen  challenge, histamine was shown to be released after 
exposure to adenosine.56 The result of in vivo studies are futher supported 
by in vivo finding: different studies have shown that inhalated adenosine, or 
AMP, provoke strong broncoconstriction in ashmatic patients, but not in 
healthy subjects,57 and elevated concentrations of adenosine were observed 
in BALF of asthmatic patients.58 
There is increasing evidence to suggest that A2BAR are responsible for the 
degranulation of mast cells.55,57,59,60-63 In the human mast cell line HMC-1, 
adenosine A2B receptor are also linked to the pathogenesis of asthma, partly 
by the so called “enpropylline paradox”. Enpropylline has a potent anti-
asthmatic action that has been attributed to its ability to block A2BAR, but 
with low affinity and selectivity.19,59,64 It has also been shown that the re-
lease of some inflammatory cytokines such as IL-8 and IL-6 from different 
cells is mediated by the activation of A2B subtypes.41,59,63 The lack of selec-
tive A2BAR ligands justifies the development of an effective and selevtive 
antagonists in order to validate this receptor as therapeutic target in asthma. 
The A2BAR antagonists that have being investigated for the treatment of 
asthma are now in Phase I and II trials.  
CVT-6883 (compound 32, see Table 2 and 3, Chapter 2) is a selective, po-
tent and orally available A2BAR antagonist. CV Therapeutics has initiated a 
clinical program for CVT-6883 intended to treat asthma with once a day 
dosing. A randomized, double-blind, placebo-controlled, single-dose phase I 
study of oral CVT-6883 in 24 healthy adults is assessing the safety and tol-
erability of a range of doses of CVT-6883. Blockade of the A2BAR may 
The A2B Adenosine Receptor 
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limit or prevent mast cell degranulation, which can lead to bronchoconstric-
tion and the inflammatory process associated with asthma and cardiopul-
monary disease. In a recent study, mice deficient in Adenosine deaminase 
(ADA) developed severe pulmonary inflammation and injury, which could 
be attenuated by CVT-6883 treatment. This compound was also able to de-
crease elevated proinflammatory cytokine lung levels in ADA-deficient 
mice. CVT-6883 also suppressed the increased expression of matrix metal-
loproteinases and their inhibitors, as well as pulmonary fibrosis, developed 
by mutant mice. ADA deficiency was also related with enhanced lung ex-
pression of adenosine and A2BAR, the levels of which tended to be lower in 
the presence of CVT-6883. In a mouse model of bleomycin-induced pulmo-
nary fibrosis, lung injury was successfully reduced by CVT6883. CVT6883 
also attenuated the airway reactivity induced by 5’-N-ethyl-carboxamide 
adenosine (NECA), AMP, or allergen in an allergic mouse model of 
asthma.65 Together, these results suggest that antagonizing A2BAR may be 
beneficial in the management of chronic pulmonary diseases. Results from a 
randomized, double-blind, placebo-controlled, single ascending dose phase 
I clinical study of CVT-6883 indicated that it was well tolerated with no 
serious adverse events reported.66 CVT-6883 has been patented for asthma 
and COPD.67 Moreover A2BAR antagonists have been claimed for use in 
promoting the healing of wounds caused by mechanical, chemical or ther-
mal activity, for example for diabetic ulcer.68 MRE2029F20 (compound 16, 
see Table 2 and 3, Chapter 2) is one of several high-affinity antagonists of 
King Pharmaceuticals's in preclinical phase. This compound has been re-
ported to be a potent and selective A2B antagonist able to counteract stimula-
tion of cAMP levels from in vitro studies performed in HEK293 cells and in 
inflammatory cells relevant for asthma like neutrophils, lymphocytes and 
HMC1 cells.69 Several A2B antagonists have been patented for asthma and 
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eye disorders.70 Other interesting A2B antagonists in preclinical phase in-
clude MRS1754,71 MRS1706,71 MRS1668,71 PSB-111572 developed at Na-
tional Institutes of Health (NIH) and PSB 53,72 from the University of Bonn. 
Therapeutic potential of A2B adenosine receptor agonists 
Ischemic preconditioning (IPC) is a cardioprotective mechanism according 
which brief and repeated episodes of sub-lethal ischemia and reperfusion, 
before myocardial infarction, cause the heart to become resistant to infarc-
tion and result in attenuation of infarct size. Activation of cardiac A2B recep-
tors at reperfusion showed to be protective in the rabbit but, because of the 
very low affinity of the receptors, endogenous cardiac adenosine is unable 
to elicit their signalling. Protein kinase C physiologically increases the 
heart's sensitivity to adenosine so that endogenous adenosine can activate 
A2B-dependent signalling. BAY 60-6583, a highly selective A2B agonist,73 
limited infarct size when given to rabbit ischemic hearts at reperfusion.74 
Postconditioning protects the heart with multiple brief reperfusion/ischemia 
cycles immediately following the ischemic insult. In rabbit hearts, binding 
of endogenous adenosine to A2B receptors in early reperfusion is a require-
ment for both IPC and postconditioning to limit infarction.75  
A pharmacological and gene-targeting approach, performed with mice mod-
els to study the contributions of adenosine receptor signalling to ischemic 
preconditioning cardioprotection, gave evidences that selective A2BAR ago-
nists may offer important advantages in comparison with classical therapies 
of acute myocardial ischemia.76 Intravenous administration of the non-
selective adenosine is associated with side effects (bradycardia, hypoten-
sion, rapid receptor desensitization) which could be circumvented by the use 
of  specific A2BAR agonists.28 
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Deletion of the gene encoding the A2BAR in the mouse (A2BAR-knockout 
mouse model) recently showed to result in increased production of proin-
flammatory cytokines, altered response to endotoxin exposure, increased 
leukocyte adhesion and increased leukocyte rolling on blood vessels.77 Acti-
vation of A2BAR subtype would moreover increase production of the anti-
inflammatory cytokine IL-10.78 
The described association of A2BAR with pre/postconditioning cardioprotec-
tion along with the documented  strong antinflammatory role of A2BAR sig-
nalling,77 suggest that A2BAR agonists may represent a new group of thera-
peutics for patients suffering from coronary artery disease. Several reports 
contribute to strengthen this perspective, highlighting essential A2B-
mediated cardiovascular effects. A NECA-mediated coronary vasodilation 
via the A2BAR subtype in isolated hearts from young (1-2 months) and ma-
ture (12-18 months) Wistar rats, has been documented.79 Adenosine-
mediated vasorelaxation in mouse aorta is partially dependent on A2BAR,80 
besides, A2B ARs mediate relaxation in human small resistance-like coro-
nary arteries which is independent of NO but partly coupled to K+ channels 
function.81 
Human aortic smooth muscle cells (SMCs) synthesize adenosine which 
seems to protect against vasoocclusive disorders by inhibiting SMCs prolif-
eration and collagen synthesis via activation of A2B receptors.82 Apoptosis of 
arterial smooth muscle cells (ASMCs) could play an important role in the 
pathogenesis of atherosclerosis and restenosis. Recent results indicate that 
adenosine-induced apoptosis of cultured human ASMCs is essentially me-
diated via A2B-adenosine receptor and involves a cAMP-dependent path-
way.83 These studies speculated that adenosine could play a dual role in the 
evolution of intimal thickening. Its action can be considered beneficial for 
what concerning the control of intimal hyperplasia and thickening forma-
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tion. In contrast, the same authors indicated that adenosine could contribute 
to the formation of the necrotic core in advanced atherosclerotic lesions 
promoting, along with other concurrent factors, the plaques rupture. These 
opposing effects suggest different therapeutic strategies based on the role of 
A2BARs stimulation-mediated effects in the pathogenesis of atherosclerosis 
and restenosis. Glomerular mesangial cells (GMCs) growth is inhibited by 
activation of A2B receptors coupled to inhibition of mitogen-activated pro-
tein kinase (MAPK) activity.84 A2BAR function may therefore largely affect 
glomerular remodeling associated with GMC proliferation. Identification of 
pharmacological agents able to specifically activate A2B receptors has been 
supposed of therapeutic importance in protecting against glomerular remod-
eling associated with glomerulosclerosis, renal disease, and abnormal GMC 
growth associated with hypertension and diabetes.  
Studies performed by Shiseido Research group would state that adenosine, 
via A2BAR, might stimulate hair growth through fibroblast growth factor-7 
gene expression upregulation in dermal papilla cells.85 
In the research field concerning the vasculogenic erectile dysfunctions 
emerged a key importance of purinergic transmission for initiation and 
maintenance of penile erection.86 Endothelial dysfunction of human corpus 
cavernosum may be correlated with the loss of adenosine A2B receptors ac-
tivity indicating a possible employment of specific A2BAR agonists as new 
therapeutic approach to manage severe vasculogenic impotence resistant to 
common vasodilators.87 Since interaction of adenosine with A2B receptors 
inhibits production of the pro-inflammatory cytokine Tumor Necrosis Fac-
tor (TNFa) by lipopolysaccharide activated monocytes,77,88 A2B agonists 
have been proposed for treatment of septic shock, confirming the broad anti-
inflammatory potential of AR agonists in treatment of inflammatory dis-
orders.89  
  
 
Chapter 2 
 
 
Medicinal Chemistry of 
Xanthine-based A2B Adenosine 
Receptor Antagonists 
 
 
 
 
The pharmacological evidence of the therapeutical applications of A2BAR 
antagonists has stimulated the research for the development of potent and 
selective ligands for this subtype. Among the different potential therapeutic 
applications postulated for the A2BAR antagonists treatment of asthma 
seems the most interesting and promising therapeutic goal.  
Xanthine derivatives represent most of the high affinity Adenosine receptor 
antagonists. 
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Due to its clinical relevance, much research is devoted to the development 
of A2B AR antagonists. 
On the bases of chemical structure and biological activity of xanthine-based 
A2B antagonists the new series of 8-heterocycles xanthine were designed and 
will be discussed in this PhD thesis. An overview of previous A2B antago-
nists is described in this chapter. 
Table 2 and 3 present the most important xanthine derivatives as A2B an-
tagonists and relative biological data respectively reported in literature. 
Research on the adenosine A1, A2A, and A3 receptors indicated that xanthi-
nes contain a promising core structure, modification of which led to the 
identification of selective antagonists for these three receptor subtypes. Ini-
tial efforts to develop antagonists selective for adenosine A2B receptor fo-
cused therefore on this class of compound. 
The natural compound caffeine (1,3,7-trimethylxanthine, 1) and theophyl-
line (1,3-dimethylxanthine, 2) are examples of compounds with a xanthine 
core strucure and both of them have micromolar affinities for all adenosine 
receptors (see tables 2, 3).90 
Theophylline is used therapeutically for the treatment of asthma and even if 
it has been in clinical use for decades, the mechanism of action through the 
adenosine A2B receptor has just recently been identified.90 The application of 
theophylline in the treatment of asthma is, however, accompanied with un-
pleasant side-effects such as insomnia and diuresis. Moreover, theophylline 
has a low therapeutic index due to its interaction with phosphodiesterase 
enzyme (PDE) and side effects in the Central Nervous System (CNS). Iden-
tification of selective adenosine A2B receptor antagonist is therefore desir-
able. Initial attempts to obtain selective antagonists for the adenosine A2B 
receptor yielded the xanthine analog enprofylline (3-propylxanthine, 3). The 
affinity of this compound for the human adenosine A2B receptor ranged 
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from 4.7 to 23 µM. Like theophylline, the treatment of asthma with en-
profylline is based on its interaction with the adenosine A2B receptor.90 
Several research groups have synthesized 8-phenyl substituted xanthines 
that have shown high A2B AR affinity and selectivity against the other AR 
subtypes. 
The phenyl ring at the 8-position of xanthine core was introduced by Muller 
and co-workers.91 1,3-disubstituted-8-(p-substituted-phenyl)-xanthine de-
rivatives were reported as A2B adenosine antagonists (compounds 4-7, table 
2). In order to increase the water solubility polar groups, basic or acid func-
tions, were introduced into the para-position of the phenyl ring.72 
Jacobson and co-workers have been also demonstrated that the introduction 
of a para-substituted phenyl derivative at the 8-position of the xanthine core 
increases the A2BAR affinity and selectivity against the other AR as illus-
trated in table 2 and 3.92 In particular, two different series of compounds, 
with a substituted phenyl moiety at the 8 position of xanthine nucleus, have 
been developed by Jacobson et al.: the 8-phenylxanthine carboxylic conge-
ner (XCC) reported as a selective A2B antagonists (table 2 and 3) and the 
series of the corresponding xanthine amino congener (XAC).  
The most selective antagonist among a large series of XAC and XCC de-
rivatives was the analog MRS1204 (10). It possessed a low nanomolar af-
finity for the A2B receptor and at least 20-fold selectivity over the other AR 
subtype. The structural analogs MRS1706 (11) and MRS1754 (12) had an 
even higher affinity for the human adenosine A2B receptor than MRS1204 
(10), 1.4 and 2.0 nM versus 9.8 nM as it is shown in Tables 2 and 3. 
Zablocki et al. used MRS1754 as a reference compound to synthesize a se-
ries of metabolically more stable analogs by replacing the anilide moiety.93  
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In particular the authors prepared the amide surrogates analogs of MRE1754 
such as 8-(4-((3-phenyl-1,2,4-oxadiazol-3-yl)methoxy)phenyl)-xanthine and 
8-(4-((5-phenyl-1,2,4-oxadiazol-3-yl)methoxy)phenyl)-xanthine analogs.  
The oxadiazole is a constrained amide surrogate that led to a different SAR 
result than the anilide series previously described by Jacobson and co-
worker. In direct contrast with the 3-phenyl-1,2,4-oxadiazole series, that 
prefer electron-withdrawing groups (EWG) substituents on the phenyl ring, 
the 5-phenyl-1,2,4-oxadiazole series favors electron-donating (EDG) groups 
in relation to affinity for the A2BAR. It was identified a clear trend with re-
spect to phenyl substitution and affinity for the A2B AR within the 5-phenyl-
1,2,4-oxadiazole series: MeO > Me > F = CF3 > Cl. Among this series, CVT 
5440 (13) had the highest selectivity and an affinity of 50 nM for the adeno-
sine A2B receptor. The analog of CVT 5440, conpound 14, showed a loss of  
affinity for A2BAR (hA2B Ki = 1680 nM).93 
In this field of research, Baraldi et al. published a series of 8-heterocycle-
substituted xanthines as A2B adenosine receptor antagonists.79,94  
Several heterocycles, such as pyrazole, isoxazole, pyridine, and pyridazine 
at the 8-position of the xanthine nucleus, were studied. The synthesized 
compounds showed A2BAR affinity in the nanomolar range and good levels 
of selectivity evaluated in radioligand binding assays at hA1, hA2A, hA2B, 
and hA3 ARs. These studies allowed to identify the derivatives 2-(3,4-
dimethoxy-phenyl)-N-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-
purin-8-yl)-1-methyl-1H-pyrazol-3-yl]-acetamide (MRE2028F20, 15),  
N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-
1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide (MRE2029F20, 
16), and N-(3,4-dimethoxy-phenyl)-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-
tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide 
(MRE2030F20, 17 Tables 2, 3), which showed high affinity to the A2BAR 
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subtype and very good selectivity vs the other AR subtypes. Substitution of 
the acetamide with an urea moiety afforded bioisosteric xanthines with good 
affinity and selectivity comparable to the acetamide derivatives. The 8-
heterocycles-substituted xanthine with higher affinity to hA2BAR proved to 
be antagonists, in the cAMP assay, capable of inhibiting the stimulatory 
effect of NECA (100 nM) with IC50 values in the nanomolar range and a 
trend significantly related to that observed in the binding assay. Conse-
quently, Baraldi and co-workers synthesized the N-benzo[1,3]dioxol-5-yl-2-
[5-(1,3-diallyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-
pyrazol-3-yloxy]-acetamide that led to prepare the tritium labelled form 
[3H]MRE2029F20, (KD value of 1.65±0.10 nM in Chinese Hamster Ovary 
(CHO) cells expressing hA2B receptors). This compound was found to be a 
selective, high-affinity radioligand useful for characterizing recombinant 
hA2B receptors.24 
Starting from the discovery of N-(2-chlorophenyl)-2-(4-(2,6-dioxo-1,3-
dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1H-pyrazol-1-yl)-acetamide (18) 
a new series of 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-
xanthine derivatives have been synthesized by Zablocki and co-worker.95 
These new compounds possess a N-substituted pyrazole at the 8 position of 
the xanthine nucleus. Also in these series the amide bonds have been re-
placed with a wide variety of structural moieties in attempts to achieve 
metabolic stability and oral bioavailability. Heterocyclic 5-membered ring 
such as 1,2,4-oxadiazoles, oxazoles and isoxazoles have been extensively 
used as amide bond bioisosteres.96 Taking into account, they replaced the 
amide bond in the compound 19 with different oxadiazoles and isoxazoles. 
In this study three different series of compound  have been synthesized and 
evaluated vs the four AR subtypes (19-23). 
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The replacement of the amide bond compound 18 (hA1 Ki = 102 nM, hA2A 
Ki = 1500 nM, hA2B Ki = 22 nM, hA3 Ki = 1200 nM) with 1,2,4-oxadiazole 
resulted in compound 19 (hA1 Ki = 2500 nM, hA2A Ki = 2500 nM, hA2B Ki = 
19 nM, hA3 Ki = 490 nM) that displayed similar binding affinity for the A2B 
AR compared to compound 18. The authors observed that, in the new series 
of compounds, derivatives that incorporated EWD groups in the phenyl ring 
displayed higher affinity and selectivity for the A2B AR relative to those hav-
ing EDG substituents. The unsubstituted phenyl analog 20 exhibited very 
high affinity (hA2B Ki = 1 nM) and selectivity for the A2B AR and suggests 
that in the 3-phenyl-1,2,4-oxadiazole class of compounds, unsubstituted 
phenyl ring is optimal for both A2B AR binding affinity and selectivity.  
Among 5-phenyl-1,2,4-oxadiazole series, the regio isomer of compound 20, 
derivative 21 showed a decrease of selectivity and affinity for A2B AR but a 
strong EWD in the 3-position of the phenyl ring (3-CF3) provided the most 
active and selective analog 22 ( hA1 Ki > 6000 nM, hA2A Ki > 5000 nM, 
hA2B Ki = 21 nM, hA3 Ki = 1300 nM). The remaining compounds of the 
series displayed a slight decrease of activity respect of previous series de-
rivatives. One could envision the 5-phenylisoxazole series as a direct analog 
of the 5-phenyl-1,2,4-oxadiazole series where the 4-nitrogen atom in the 
isoxazole ring is isosterically replaced with a carbon atom such as in com-
pound 23. In general this third series was less active and selective for A2B 
AR in comparison to the other oxadiazole classes of compounds as it is 
shown in tables 2 and 3.95 
Another series of 8-pyrazole xanthine derivative was patented by Kalla et al. 
as A2B AR antagonists. The new series of compounds displayed good affin-
ity and selectivity for the A2B subtype and confirming the relevance of a 
pyrazole ring at 8-position of xanthine nucleus.97 Kalla and co-worker ana-
lyzed the substitution of the pyrazole ring at the 8-position of xanthine core 
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and synthesized three different series of compounds: 8-(N-1-pyrazolyl) xan-
thine, 8-(C5-pyrazolyl) xanthine and 8-(4-pyrazolyl) xanthine. 
The 8-(N-1-pyrazolyl) xanthine derivatives, 24-26 demonstrated low affin-
ity for the A2BAR. This suggests that this mode of pyrazole attachment is 
not conductive for binding to A2BAR. Also 8-(C5-pyrazolyl) xanthine de-
rivatives 27-29 showed weak binding affinities (in the range of 1-3 µM) for 
the A2BAR.97 
Instead the incorporation of C4-pyrazole ring at the 8-position of the xan-
thine nucleus resulted in high affinity and low selectivity for A2BAR sub-
types. The two options for increasing the binding selectivity were to change 
the substitution either at the N-1 position of the pyrazole or at the N-1 and 
N-3 positions of the xanthine core. Starting from the compound 30 of the 8-
(4-pyrazolyl) xanthine series, characterized by a phenyl ring at the N-1 posi-
tion of pyrazole group (hA2B Ki = 310 nM), the importance of the spacer 
between the phenyl and the pyrazole ring was investigated by Kalla et al. 
The introduction of a benzyl group at the N-1 position of pyrazole ring re-
sulted in compound 31 which displayed slightly enhanced selectivity over 
A1 AR. The effect of introducing of EDG and EDG groups on the phenyl 
ring was investigated with the goal to enhancing its A2B affinity and selec-
tivity. The best compound of this series was CVT6883, 32 (hA2B Ki = 14 
nM).97 
Increasing the distance between the phenyl group and the N-1 position of 
pyrazole ring from one carbon atom to two carbon atoms, as in compounds 
33 and 34, resulted in a decrease in affinity and selectivity for the A2BAR 
relative to 31. After this study, the effect of varying the dialkyl substitution 
of the xanthine core N-1 and N-3 on A2BAR affinity and selectivity was 
evaluated and they confirmed that 1,3-diproyl xanthine derivatives showed 
the best results in terms of both affinity and selectivity. 
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Continuing the research of 8-pyrazole xanthine derivatives, Baraldi and co-
worker developed and characterized a new series of compounds 35-41 ob-
tained by replacement of the side chain from the 3-position of the pyrazole 
ring of the MRE series to the 1-position.98 As it is shown in Tables 2 and 3, 
the synthesis of this new class of 8-(pyrazole-3-yl) xanthine derivatives led 
to the identification of several A2BAR antagonists with high affinity and 
very good selectivity for the adenosine receptor subtypes. Different posi-
tions in phenyl ring of the xanthine-based structure were investigated in 
order to design a SAR profile. In particular were prepared derivatives to 
study the effect of substituting the 3-and/or 4-position of phenyl ring with 
EDG and EWG groups. The substitution at the para-position of the phenyl 
ring with EWG groups, such as halogen atoms, resulted in an increase of 
selectivity while retaining affinity at the A2B receptor (35-37 derivatives). 
The 4-chloro-phenyl derivative 35 was found to be the most potent (Ki hA2B 
= 7 nM) and selective compound within the series (A1, A2A, A3/A2B > 140). 
The substitution at the para-position of the phenyl ring with EDG moiety, 
(38, 39) also showed good affinity at the A2B, retaining selectivity at AR 
subtypes while bulky lipophilic groups led to a loss of affinity. Shifting of 
substituents from the para-position to the meta-position of the phenyl ring 
resulted in compounds with lower binding affinity at the A2B receptor com-
pared to the corresponding para-position derivatives. Disubstituted phenyl 
analogues which contain a 3,4-substituent were found to have lower A2B AR 
affinity than mono-substituted analogues. Moreover the effect of substitu-
tion of methyl group at the 5-position of pyrazole was investigated. The 
presence of ethyl moiety at the 5-position (40) led to a loss of affinity and 
the derivative with hydrogen atom at the same position (41) displayed a 3-
fold decrease of affinity and selectivity compared to the reference com-
pound 35. In this study was also explored the effect of 4-substituted pyra-
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zoles on A2B AR affinity with the 4-halo-derivatives that resulted in a loss of 
affinity compared to unsubstituted derivative 35.98  
 
9-Deaza Xanthine-based Derivatives 
Another subclass of xanthine core, the 8-substituted-9-deazaxanthines also 
yielded derivatives with nano molare affinity for the adenosine A2B receptor. 
The most potent antagonist, C8-4-aminophenyl, 1,3-dipropyl-9-
deazaxanthine (43) was, however, poorly selective (7-fold) with respect to 
the adenosine A2A receptor.99 Moreover this compound was not tested on the 
human adenosine A1 and A3 receptors. The unsubstituted compound (42) 
was tested on all four human adenosine receptors and had the highest affin-
ity for the A1 adenosine receptor. Kalla et al.100 also described a series of 8-
substituted-9-deazaxanthines as selective A2BAR antagonists. The structure 
of two of the more potent compounds was revealed (44, 45, Tables 2, 3) and 
their affinities provided. The 3-fluorobenzyl substituted compound (44) had 
a slightly higher hA2B Ki value, 13 nM, versus 9 nM for the 3-
trifluoromethylbenzyl substituted compound (45) as it is shown in Table 2 
and 3.  
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Table 2. Xanthine-based derivatives as A2B Adenosine Antagonists 
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5-phenyl-1,2,4-oxadiazole Series
13, CVT5440  R = 3-OCH3
3-phenyl-1,2,4-oxadiazole Series
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7, R1 = C4H9, R2 = H R3 = 4-COOMe
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Table 2. Continued… 
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3-phenyl-1,2,4-oxadiazole Series
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9-Deaza Xanthine derivatives A2B Adenosine Antagonists 
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8-(5-pyrazolyl)-xanthine Series
8-(4-pyrazolyl)-xanthine Series
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27, R = H, R1 = R2 = CH3
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N
N N
H
N
O
O
N
N
N
H
O
R1
8-(3-pyrazolyl)-xanthine Series
35, R = CH3, R1 = 4-Cl
36, R = CH3, R1 = 4-Br
37, R = CH3, R1 = 4-I
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41, R = H, R1 = 4-Cl
R
N
N
H
N
O
O
R1
N
N
H
N
O
O
N
N
R3
42, R = H
43, R = NH2
44, R1 = H, R2 = F
45, R1 = OH, R2 = CF3
   27 
 
*Table 3. Biological affinity of the A2BAR antagonists.  
*Experimental conditions for biological assays are reported in the cited references. 
Ki nM  
Compound hA1 hA2A hA2B hA3 
190 10700 9560 10400 - 
290 6800 1700 6700 86000 
390 156000 32000 7000 65000 
491 - - 810  
591 - - 3.8 -- 
672 - - 24 - 
772 - - 15.1 - 
892 6.8 18 7.8 26 
992 175 595 13.6 3,910 
1092 153 127 9.8 227 
1192 157 112 1.4 230 
1292 403 503 2.0 570 
1393 > 10000 > 5000 50 > 8350 
1493 > 6000 > 5000 1680 - 
1594 > 1000 > 1000 38 > 1000 
1694 200 > 1000 5.5 > 1000 
1794 > 1000 > 1000 41 > 1000 
1895 102 1500 22 1200 
1996 2500 2500 19 490 
2096 370 1100 1 480 
2196 1000 1800 21 630 
2296 > 6000 > 5000 21 1300 
2396 2300 1700 48 1200 
2497 - - > 5800 - 
2597 - - > 5800 - 
2697 - - > 5800 - 
2797 - - 3700 - 
2897 - - 2100 - 
2997 - - 1100 - 
3097 - - 310 - 
3197 76 290 11 - 
3297 170 400 14 - 
3397 17 570 74 - 
3497 77 220 100 - 
3598 > 1000 > 1000 7 > 1000 
3698 > 1000 > 1000 35 > 1000 
3798 > 1000 > 1000 28 > 1000 
3898 > 1000 > 1000 56 > 1000 
3998 > 1000 > 1000 12 > 1000 
4098 > 1000 > 1000 > 1000 > 1000 
4198 140 > 1000 20 > 1000 
4299 34 646 229 95 
4399 - 112 17 - 
44100 - - 13 - 
45100 - - 9 - 
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Design and synthesis of new  
A2B Adenosine Antagonists 
 
 
 
 
 
 
 
The new A2BAR antagonists were designed and synthesized on the basis of  
previouse chemical structure of our 8-pyrazolyl-xanthines. This chapter 
describes the synthesis and the pharmacological properties of a set of new 
8-heterocycle-xanthines that confirm the A2B selectivity of this xanthine 
class of compounds. 
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Starting from chemical structure of MRE2029F20,94 a new series of A2B 
antagonists has been designed and synthesized. As shown in Figure 4, vari-
ous structural modifications were realized using the previously reported 
chemical structure of 8-[(pyrazol-3-yloxy)-acetanilide)] xanthine94 as a tem-
plate. 
 
Figure 4 .Structure modifications considered MRE2029F20 as a template. 
 
 
 
 
 
 
 
 
 
 
 
 
The bioisosteric replacement of the anilide moiety with benzimidazole or 
quinazoline rings, the effect of the substitution of pyrazole with isoxazole 
moiety was investigated. Amide bond has been also replaced with the 5-
phenyl-1,2,4-oxadiazole nucleus on the basis of other adenosine pharma-
cophores such as those reported previously by Zablocki et al.93 
In this context the effect of the nitrogen at the 9-position has been also stud-
ied preparing four 9-deaza direct analogs of 8-pyrazol-xanthine compounds 
to compare affinity  and selectivity at A2B adenosine receptor.  
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The compounds described in this report are shown in Tables 4-7, Chapter 4 
and their syntheses are outlined in Schemes 1-4. The carboxylic acid 94 deri-
vatives 48 or 68, in anhydrous dimethylformamide (DMF), were condensed 
with phenylendiamines (2-amino-benzamide for compound 66) using 1-[3-
(dimethyl-amino)-propyl]-3-ethylcarbodiimide hydrochloride (EDC) to fur-
nish the amides that were subsequently cyclized in the presence of acetic 
acid at 80-100 °C  to provide the 8-heteroaryl derivatives 49-66 and 69-76 
(Scheme 1 and 2). 
Scheme 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents: i: a. 1,3-dipropyl-5,6-diamino-uracil (47), EDC, methanol, rt; b. NaOH, 
80 °C; ii: a. 2-amino-benzamide, EDC, DMF, rt, b. CH3CO2H, 80 °C; iii: a. appro-
piate diamine, EDC, DMF, rt; b. CH3CO2H, 80-100 °C. 
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Scheme 2 
 
 
 
 
 
 
 
 
 
Reagents: i: a. 1,3-dipropyl-5,6-diamino-uracil (47), EDC, methanol, rt; b. NaOH, 
80 °C; ii: a. appropiate diamine, EDC, DMF, rt; b. CH3CO2H, 80-100 °C.  
 
The target xanthine derivatives 85, 86 were prepared as shown in Scheme 3. 
3-Benzyloxy-1-methyl-1H-pyrazole-5-carboxylic acid 79 was prepared by 
direct alkylation of ethyl 1H-pyrazole-4-carboxylate94 77 with benzyl chlor-
ide in acetone using K2CO3 as a base, followed by ester hydrolysis. Cou-
pling of 79 with 1,3-dipropyl-5,6-diaminouracil101 using EDC afforded the 
amidic intermediate, which was cyclized in NaOH to afford compound 80. 
Debenzylation with ammonium formate and palladium on carbon yielded 
the target compound 86.  
Treatment of 80 with 2-(trimethylsilyl)-ethoxymethyl chloride (SEM-Cl) 
and K2CO3 introduced the SEM protection group at N-7. Debenzylation 
yielded our key intermediate 82. This Compound was then alkylated with 3-
chloromethyl-5-(3-methoxy-phenyl)-[1,2,4]oxadiazole (83)95 to yield 84. 
SEM deprotection with 3 N HCl in ethanol at 80 °C afforded the target 
compound 85.  
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Scheme 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents: i: benzyl bromide, K2CO3, acetone, rt; ii: KOH, dioxane, rt; iii: a. 1,3-
dipropyl-5,6-diamino-uracil (47), EDC, methanol, rt; b. NaOH, 80 °C; iv: Pd/C, 
HCO2NH4, methanol, rfx; v: SEM-Cl, K2CO3, DMF, 70 °C; vi: 3-chloromethyl-5-(3-
methoxy-phenyl)-[1,2,4]oxadiazole (83), K2CO3, acetone; vii: HCl, ethanol, 90 °C. 
 
The synthesis of 9-deaza-xanthines 92, 98-100 analogs was performed in 
knowledge to published procedures102,103 with some modifications to reflect 
the change from benzaldehyde to the pyrazolo aldehyde (Schemes 4, 5). 
Pyrazolo aldehyde 88 was prepared by conversion of 87 into a mixed an-
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dride to yield the corresponding alcohol, which was reacted with the pyri-
dinium chlorocromate (PCC) (Scheme 4). Condensation of the 1,3-dipropyl-
6-methyl-5-nitrouracil104 (89) with the 3-benzyloxy-1-methyl-1H-pyrazole-
5-carbaldehyde 88 in dry benzene and catalytic morpholine allowed us to 
obtain the corresponding (E)-6-styryl derivative 90 in satisfactory yields. 
The ring closure of 90 to intermediate 91 was performed by reductive 
cyclization using iron in acetic acid under reflux. Debenzylation of 91 in a 
manner similar to that for the synthesis of 86, yielded the deaza derivative 
92 (Scheme 4).  
Scheme 4 
 
 
 
 
 
 
 
 
 
 
Reagents: i: a. ClCO2Et, TEA, NaBH4 , THF, -10°C; b. PCC, CH2Cl2, rt; ii: 1,3-
dipropyl-6-methyl-5-nitro-uracil (89), morpholine, pTsOH, toluene, rfx; iii: Fe, 
CH3O2H, ethanol, rfx; iv: HCO2 NH4, Pd/C, methanol, rfx.   
 
The target 9-deaza derivatives 98, 99, 100 were prepared by the same syn-
thetic route reported for compound 92 starting from the pyrazolo carboxylic 
acid 9394 to afford the intermediate pyrrolo[3,2-d]pyrimidin-6-yl)-pyrazol-3-
yloxy]-acetic acid 97 (Scheme 5). Target compound 98 was obtained as the 
same procedure used for analogs 50-65, while direct condensation of car-
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boxylic acid 97 and the suitable anilines in DMF in the presence of 1-[3-
(dimethylamino)-propyl]-3-ethylcarbodiimide hydrochloride (EDC) as cou-
pling reagent yielded 99 and 100. 
Scheme 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents: i: a. ClCO2Et, TEA, NaBH4, THF, -10 °C; b. PCC, CH2Cl2, rt; ii: 1,3-
dipropyl-6-methyl-5-nitro-uracil (89), morpholine, pTsOH, toluene, rfx; iii: Fe, 
CH3CO2H, ethanol, rfx; iv: NaOH 10%, methanol; v: a. 1,2-phenylendiamine, EDC, 
DMF, rt; b. CH3CO2H, 60 °C; vi: aniline, EDC, DMF, rt.  
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 Chapter 4 
 
 
 
Results and Conclusions 
 
 
 
In this chapter are reported the biological data of compound have been 
investigated. All the 8-heterocycle-xanthines were evaluated in radioligand 
binding assays to determine their affinities for human A1, A2A, A2B and A3 
adenosine receptors. It has been used [3H]-DPCPX (1,3-[3H]-dipropyl-8-
cyclopentylxanthine) for A1 and A2B, [3H]-ZM 241385 (4-(2-[7-amino-2-(2-
furyl)[1,2,4]-triazolo[2,3-a][1,3,5]triazin-5-ylamino]-ethyl)-phenol), and 
[3H]-MRE3008F20 (5-N-(4-methoxyphenylcarbamoyl)amino-8-propyl-2-(2-
furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) for A2A and A3 re-
spectively, as radioligands. Efficacy of the compounds versus hA2BAR was 
also investigated evaluating their capability to inhibit (100 nM) NECA 
stimulated cAMP production (Table 4-7).  
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Binding affinities of the synthesised compounds for the, A1, A2A, A3 and 
A2BARs are presented in Tables 4-7. The SAR of the benzimidazol-
methoxy-pyrazole and benzimidazol-methoxy-isoxazole analogues with 
respect to the A2BAR affinity are shown in Table 4, 5. A general comparison 
of similarly substituted phenyl analogues between the pyrazole and isoxa-
zole series (e.g. 52 vs 70, 55 vs 72, etc) favours the pyrazole series with 
respect to the selectivity versus the A1 receptor. 
As shown in Table 4, the parent unsubstituted phenyl analog 50 was highly 
potent at the human A2B receptor, with a Ki value of 18 nM, although not 
selective for A2B vs A1 receptors (hA1/hA2B = 12). The 5-substituted-phenyl 
analogs 51-60 showed high affinity for the A2BAR and the best compound 
was 5-Cl derivative 52 (hA2B Ki = 5 nM). Introducing a stronger electron-
withdrawing group (Br or CF3) in place of the 5-Cl group, as in compounds 
54 and 55 resulted in 2-3-fold loss in binding affinity (54, hA2B Ki = 15.9 
nM; 55, hA2B Ki =8.1). However, compound 55 improved selectivity for the 
A2AR versus the A1AR. The 5-F derivative 51 exhibited lower affinity and 
selectivity in comparison to 5-Cl 54.  
Introduction of substituents containing carbonyl function such as 5-
carboxylic acid ethyl ester 59 produced good affinity and selectivity for 
A2BAR (hA2B Ki = 12 nM A1/A2B = 42). The carboxylic acid derivative 60 
exhibited less affinity at both A1 and A2B receptors (hA2B Ki = 88, A1/A2B = 
52). The 5-nitro analog 58 showed 3-fold lower affinity although compa-
rable selectivity for the A2BAR relative to the 5-Cl analog 54.  
Substitution of the phenyl ring with the naphthyl nucleus produced com-
pound 57 that had similar binding affinity (hA2B Ki = 20 nM) to the phenyl 
analog 50, while it showed nearly 10-fold more selectivity for the A2BAR 
versus A1, relative to 50 suggesting an increased binding domain in the A2B 
receptor versus the A1AR. 
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Table 4. Chemical structure and biological activity at ARs of 1,3 dipropyl-8-(3-
benzoimidazol-yl-methoxy-1-methyl-pyrazol-5yl) xanthine derivatives. 
 
 
 
 
 
 
 
Comp. R hA1b hA2Ac hA2Bd hA3e cAMP hA2B 
  Ki (nM)a IC50 (nM) 
50 
 
H 
 
222 
(181-273) 
> 1000 
 
17.9 
(12.6-25.6) 
> 1000 
 
65 
(56-75) 
51 
 
5-F 
 
645 
(560-744) 
> 1000 
 
30 
(24-39) 
> 1000 
 
95 
(86-105) 
52 
 
5-Cl 
 
150 
(107-210) 
> 1000 
 
5.0 
(3.6-7.0) 
> 1000 
 
15 
(11-21) 
53 
 
5-OCH3 
 
752 
(665-851) 
> 1000 
 
14.2 
(7.8-25.7) 
> 1000 
 
54 
(39-76) 
54 
 
5-Br 
 
280 
(245-319) 
> 1000 
 
15.9 
(14.5-17.3) 
> 1000 
 
65 
(56-75) 
55 
 
5-CF3 
 
576 
(532-625) 
> 1000 
 
8.1 
(4.6-14.1) 
> 1000 
 
38 
(31-52) 
56 
 
5-CH3 
 
736 
(666-814) 
> 1000 
 
10.2 
(5.0-20.5) 
> 1000 
 
45 
(37-55) 
57 
 
5,6-C4H4 
 > 1000 > 1000 
20 
(13-30) > 1000 
80 
(63-100) 
58 
 
5-NO2 
 
155 
(133-180) 
> 1000 
 
14.8 
(10.2-21.5) 
> 1000 
 
62 
(54-72) 
59 
 
5-CO2Et 
 
503 
(476-532) 
> 1000 
 
12 
(11.4-12.5) 
> 1000 
 
35 
(29-42) 
60 
 
5-CO2OH 
 
4558 
(3953-5255) 
> 1000 
 
88 
(75-104) 
> 1000 
 
220 
(183-266) 
61 
 
4-CH3 
 
685 
(593-792) 
> 1000 
 
14.1 
(9.3-21.3) 
> 1000 
 
60 
(51-70) 
62 
 
4-Cl, 6-CF3 
 
2530 
(2267-2824) 
> 1000 
 
9.4 
(8.8-9.9) 
> 1000 
 
26 
(17-380 
63 
 
4,6-CF3 
 
4462 
(4020-4952) 
> 1000 
 
25 
(20-31) 
> 1000 
 
70 
(59-84) 
64 
 
5-Cl, 6-F 
 
210 
(192-229) 
> 1000 
 
19 
(15-24) 
> 1000 
 
32 
(24-42) 
65 
 
5,6-CH3 
 
734 
(613-879) 
> 1000 
 
22 
(16-31) 
> 1000 
 
53 
(37-75) 
 
aThe data are expressed as the geometric mean with 95% confidence limits in parentheses and derived from 
inhibition binding experiments and cAMP assays. bDisplacement of specific [3H]DPCPX binding at human 
A1 receptors expressed in CHO cells (n = 3-6). c Displacement of specific [3H]ZM241385 binding at human 
A2A receptors expressed in CHO cells (n = 3-6). d Displacement of specific [3H] DPCPX binding at human 
A2B receptors expressed in HEK293 cells (n ) 3-6). e Displacement of specific [3H]MRE3008-F20 binding at 
human A3 receptors expressed in CHO cells (n = 3-6).  
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The 5-methoxy-phenyl analog 53 and the 5-methyl analog 56 had favorable 
binding affinities for the A2BAR (hA2B Ki = 14.2 nM, hA2B Ki = 10.2 nM 
respectively). They also showed more selectivity for the A2BAR versus A1, 
relative to 52. Shifting the methyl group from the 5- to the 4-position in 
analog 61 had no significant effect on affinity or selectivity for the A2BAR 
versus A1. The 5,6-dimethyl analog 65 resulted slightly less potent at A2BAR 
(hA2B Ki = 22 nM) with also lower selectivity versus A1 receptor compared 
with 5-methyl analog 56.  
The 4,6-disubstituted analog 62 showed high affinity and selectivity at 
A2BAR. In fact, compound 62 (4-Cl, 6-CF3 ) is our most active and selective 
analog among the two classes of compounds we synthesized (hA2B Ki = 9.4 
nM A1/A2B = 269). Introducing a stronger electron-withdrawing group (CF3) 
in place of the 4-Cl group such as in compound 63 resulted in 3-fold loss in 
binding affinity (hA2B Ki =25 nM). The 5-Cl, 6-F analog 64 displayed simi-
lar affinity, with 5,6-disubstituted analog 65, even though the 5,6-dimethyl 
substitution produced 3-fold increasing of A1 selectivity. 
Compounds 69-76 were prepared by replacing the pyrazole ring with isoxa-
zole nucleus. In general, the benzimidazol-isoxazole series, was less selec-
tive for the A2BAR versus the A1AR when compared to the benzimidazole-
pyrazole class of compounds. This data is in contrast with the pyrazole-
oxyacetamide derivatives synthesised in our previous work94 that were more 
selective when compared to the pyrazole parent compounds. A similar trend 
was observed when comparing the isoxazole analog 69 to the pyrazole ana-
log 50. The 5-halogen analogs 70-72 displayed similar affinities at the 
A2BAR compared to that of the 5-halogen-substituted pyrazole analogs, but 
they were slightly less selective versus A1. A noticeable exception was the 
5-bromo analog 71 that was 4-fold more active at A2BAR in comparison to 
analog 54. Further substitution of the 5-position of the phenyl ring by a 
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methoxy group produced compound 73 that was less potent (hA2B Ki =35 
nM) than 53 (hA2B Ki =14.2 nM), and also less selective versus the A1AR.  
Table 5. Chemical structure and biological activity at ARs of 1,3 dipropyl-8-(3-
benzoimidazol-yl-methoxy-isoxazol-5yl) xanthine derivatives. 
 
 
 
 
 
 
 
 
aThe data are expressed as the geometric mean with 95% confidence limits in parentheses and derived from 
inhibition binding experiments and cAMP assays. bDisplacement of specific [3H]DPCPX binding at human 
A1 receptors expressed in CHO cells (n = 3-6). c Displacement of specific [3H]ZM241385 binding at human 
A2A receptors expressed in CHO cells (n = 3-6). d Displacement of specific [3H] DPCPX binding at human 
A2B receptors expressed in HEK293 cells (n ) 3-6). e Displacement of specific [3H]MRE3008-F20 binding at 
human A3 receptors expressed in CHO cells (n = 3-6).  
The introduction of fluorine in the ortho-position of 5-chloro analog 70 pro-
duced non-significant effects on affinity and selectivity at A2B, as shown by 
analog 74. Also in the isoxazolo series, as with the pyrazole analogues, the 
best compound was 4-Cl, 6-CF3-disubstituted phenyl analog 75 (hA2B Ki = 
22 nM, hA1/hA2B > 50) in relation to affinity at A2B and selectivity versus 
A1ARs. Introduction of trifluoromethyl at the 4 and 6 positions produced a 
Comp. R hA1b hA2Ac hA2Bd hA3e cAMP hA2B 
  Ki (nM)a IC50 (nM) 
69 
 
H 
 
277 
(227-338) 
> 1000 
 
23 
(17-30) 
> 1000 
 
74 
(65-84) 
70 
 
5-Cl 66 
(57-76) 
> 1000 3.5 
(2.9-4.2) 
> 1000 6.4 
(4.9-8.3) 
71 
 
5-Br 89 
(77-104) 
> 1000 4.1 
(2.9-5.7) 
> 1000 11 
(7-17) 
72 
 
5-CF3 175 
(134-229) 
> 1000 10.0 
(7.5-13.1) 
> 1000 51 
(38-68) 
73 
 
5-OCH3 304 
(257-361) 
> 1000 35 
(27-47) 
> 1000 114 
(86-151) 
74 
 
5-Cl, 6-F 65 
(55-78) 
> 1000 5.5 
(4.8-6.3) 
> 1000 8.0 
(7.2-8.9) 
75 
 
4-Cl, 6-CF3 > 1000 
 
> 1000 22 
(16-31) 
> 1000 64 
(50-81) 
76 
 
4,6-CF3 > 1000 
 
> 1000 76 
(65-87) 
> 1000 197 
(136-287) 
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decrease of affinity and selectivity such as compound 76 in comparison with 
analog 63. The enlargement of benzimidazole nucleus of analog 50 did not 
improve affinity at the A2BAR as demonstrated by 4-oxo-3,4-dihydro-
quinazoline 49, but did increase the selectivity 3-fold versus A1AR. Re-
placement of the phenyl ring with pyrimidine, such as in compound 66 pro-
duced a complete loss of affinity at the A2BR. The benzimidazole nucleus 
was also replaced by 5-m-methoxyphenyl-1,2,4-oxadiazole to afford analog 
85 (hA2B Ki = 70 nM). This analog displayed 5-fold lower affinity compared 
to 5-methoxy-benzimidazole analog 53.  
Table 6. Chemical structure and biological activity at ARs of 1,3 dipropyl-8-(3-
heterocycl-yl- methoxy-1-methyl-pyrazol-3yl) xanthine derivatives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comp. hA1b hA2Ac hA2Bd hA3e cAMP hA2B 
 Ki (nM)a IC50 (nM) 
49 
 
> 1000 
 
> 1000 
 
49 
(39-62) 
> 1000 
 
180 
(153-212) 
66 
 
> 1000 
 
> 1000 
 
> 1000 
 
> 1000 
 
> 1000 
 
85 
 
> 1000 
 
> 1000 
 
61 
(49-77) 
> 1000 
 
219 
(186-259) 
 
aThe data are expressed as the geometric mean with 95% confidence limits in parentheses and derived from 
inhibition binding experiments and cAMP assays. bDisplacement of specific [3H]DPCPX binding at human 
A1 receptors expressed in CHO cells (n = 3-6). c Displacement of specific [3H]ZM241385 binding at human 
A2A receptors expressed in CHO cells (n = 3-6). d Displacement of specific [3H] DPCPX binding at human 
A2B receptors expressed in HEK293 cells (n ) 3-6). e Displacement of specific [3H]MRE3008-F20 binding at 
human A3 receptors expressed in CHO cells (n = 3-6).  
 
The 8-(3-hydroxy-1-methyl-1H-pyrazol-5-yl)-xanthine 86 was synthesised 
as a simplified chemical structure of pyrazole-xanthine series. This com-
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* *49: X = 66: X = 85: X =
OCH3
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pound displayed very high affinity at A2B receptors with good selectivity 
over A1. (Table 7, hA2B Ki = 4.0 nM, hA1/hA2B = 183). The 9-deaza xanthi-
nes 92, 98-100 differing from the absence of a nitrogen atom at the 9-
position of heterocyclic system of xanthines were synthesised based on their 
noted antagonistic activity at the A2B receptor.103 
Table 7. Chemical structure and binding activity at ARs of various sets of Xanthine 
and 9-deaza Xanthine derivatives. 
 
 
 
 
Comp. 
 
X R hA1b hA2Ac hA2Bd hA3e cAMP hA2B 
   Ki (nM)a IC50 (nM) 
86 
 
N 
- 
733 
(661-812) > 1000 
4.0 
(2.5-6.4) > 1000 
20 
(14-29) 
92 
 
C 
- 140 (123-159) 
960 
(956-992) 
7.5 
(7.1-8.0) > 1000 
9 
(7.3-11) 
50 
 
N 
 
 
222 
(181-273) 
> 1000 
 
17.9 
(12.6-25.6) 
> 1000 
 
65 
(56-75) 
98 C 
 
 
34 
(27-42) 
> 1000 11.4 
(11-11.9) 
> 1000 27 
(22-34) 
99 C 
 
  
45 
(37-55) 
> 1000 13.4 
(12.5-14.4) 
> 1000 43 
(37-50) 
100 C 
 
 
55 
(46-65) 
> 1000 87 
(75-101) 
> 1000 236 
(176-317) 
101 N 
 
 
65 
(48-96) 
> 1000 12 
(7.0-21) 
> 1000 88 
(82-95) 
102 N 
 
200 
(180-226) 
> 1000 5.5 
(4.6-6.5) 
> 1000 38 
(29-51) 
aThe data are expressed as the geometric mean with 95% confidence limits in parentheses and derived from 
inhibition binding experiments and cAMP assays. bDisplacement of specific [3H]DPCPX binding at human 
A1 receptors expressed in CHO cells (n = 3-6). c Displacement of specific [3H]ZM241385 binding at hu-
manA2A receptors expressed in CHO cells (n = 3-6). d Displacement of specific [3H] DPCPX binding at 
human A2B receptors expressed in HEK293 cells (n ) 3-6).e Displacement of specific [3H]MRE3008-F20 
binding at human A3 receptors expressed in CHO cells (n = 3-6).  
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The ARs binding affinities of deaza analogs in comparison with xanthines 
are reported in Table 7. The analogs 99 and 100 were prepared comparing to 
those recently published 8-pyrazolyl oxyacetamide derivatives 101 and 102. 
In general, the new deaza analogs showed less selectivity over A1 even 
though displayed high affinity at A2BAR. 
The deaza analog 92 compared to 86 displaying 2-fold less affinity at A2B 
and 10-fold less selectivity versus A1AR. The deaza analoge 98 exhibited 2-
fold increased of affinity compared to its xanthine derivative 50 , while was 
4-fold less selective versus A1. The deaza oxyacetamides 99, 100 showed 
less affinity and selectivity at A2BAR in respect to their xanthine analogs 
101 and 102. 
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Conclusions 
We have identified new leads for the design of xanthine derivatives as selec-
tive antagonists of the A2BAR. From our study on this new class of 8-
substituted xanthine derivatives emerged a series of important considera-
tions. The most significant result was obtained by bioisosteric replacement 
of the anilide moiety with benzimidazole, achieving antagonists with high 
affinity and selectivity toward the A2BAR. In particular compounds 62, 63, 
52 and 70 showed the best biological data.  
 
 
 
 
 
 
 
 
Figure 5. Chemical structure of the most potent A2B adenosine antagonists. 
Moreover the effect of the substitution of pyrazole at 8-position of xanthine 
core with isoxazole was investigated and in general, the benzimidazol-
isoxazole series, was less selective for the A2BAR versus the A1AR when 
compared to the benzimidazole-pyrazole analogs.  
The bioisosteric substitution of the nitrogen at the 9-position of the xanthine 
nucleus with a carbon atom displayed a decrease of selectivity for the 
A2BAR while the affinity was maintained. Such selective compounds will 
aid in the elucidation of the physiological role of this receptor and possibily 
lead to therapeutilally useful agents for treating asthma, diabetes and other 
diseases. 
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 = 2530 nM
hA2A Ki  > 1000 nM
hA2B Ki 
 = 9.4 nM
hA3   Ki  > 1000 nM
hA1   Ki
 
 = 4462 nM
hA2A Ki  > 1000 nM
hA2B Ki 
 = 25 nM
hA3   Ki  > 1000 nM
hA1   Ki
 
 = 150 nM
hA2A Ki  > 1000 nM
hA2B Ki 
 = 5.0 nM
hA3   Ki  > 1000 nM
hA1   Ki
 
 = 66 nM
hA2A Ki  > 1000 nM
hA2B Ki 
 = 3.5 nM
hA3   Ki  > 1000 nM
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Chemical Materials and Methods 
Reagent grade solvents were dried according to standard techniques. So-
dium sulfate was used as a drying agent for water containing organic 
phases. Reactions were routinely monitored by thin-layer chromatography 
(TLC) on silica gel (precoated F245 Merck plates). Chromatographic spots 
were visualized by UV light. Purification of crude compounds and separa-
tion of reaction mixtures were carried out by column chromatography on 
silica gel 60 (230–400 mesh from Merck) using appropriate eluents. Melting 
points (uncorrected) were determined in a 240 Buchi-Tottoli melting point 
apparatus. Chemical shifts (d) are reported in parts per million (ppm) rela-
tive to the solvent central peak. 1H NMR spectra were recorded at 200 MHz 
on a Bruker AC 200 spectrometer. Electrospray Ionization Mass Spec-
trometry (ESI/MS) was performed with an Agilent 1100 Series LC/MSD 
model in positive scan mode. The molecular weights from the MS spectra 
(reported only for final compounds) were in full agreement with the pro-
posed chemical structures of target compounds.  
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General Procedure for the Preparation of 8-[3-(1H-Benzoimidazol-2-
ylmethoxy)-1-methyl-1H-pyrazol-5-yl]-1,3-dipropyl-3,7-dihydro-purine-
2,6-dione 50-66 and 8-[3-(1H-Benzoimidazol-2-ylmethoxy)-isoxazol-5-yl]-
1,3-dipropyl-3,7-dihydro-purine-2,6-dione 69-76.  
(Except compound 60 that was prepared from 59) 
To a mixture of the carboxylic acid (48 or 68, see Scheme 1) (0.25 mmol), 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.25 
mmol), and anhydrous Dimethylformamide (DMF) (5 mL) was added the 
appropriate phenylenediamine (0.25 mmol) and the mixture was stirred at 
room temperature overnight under argon atmosphere. The resulting solution 
was evaporated under reduced pressure, and the residue was dissolved in 
acetic acid (5 mL) and heated under stirring at 60-70 °C for 1 h. The resul-
ting solution was cooled to room temperature and poured into water. The 
precipitate was collected by filtration and washed with water . The resulting 
crude was purified by flash column chromatography on silica gel or crystal-
lized when necessary. 
8-[3-(1H-Benzoimidazol-2-ylmethoxy)-1-methyl-1H-pyrazol-5-yl]-1,3-
dipropyl-3,7-dihydro-purine-2,6-dione (50). 
Purification by crystallization from dioxane. Yield: 96%, mp: 290°C 
1H NMR (DMSO-d6): δ  0.86 (m, 6H); 1.53 (q, 2H); 1.70 (q, 2H); 3.84 (t, 
2H); 3.98 (t, 2H); 4.08 (s, 3H); 5.35 (s, 2H); 6.53 (s, 1H); 7.16-7.75 (m, 
4H); 12.63 (s, 1H); 14.00 (bs, 1H); MS m/z 443 (M H+).  
8-[3-(5-Fluoro-1H-benzoimidazol-2-ylmethoxy)-1-methyl-1H-pyrazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (51). 
Purification by column chromatography on silical gel (AcOEt). Yield: 48%, 
mp: 280°C. 
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1H NMR (DMSO-d6): δ 0.88 (m, 6H); 1.57 (q, 2H); 1.72 (q, 2H); 3.86 (t, 
2H); 4.01 (t, 2H); 4.15 (s, 3H); 5.36 (s, 2H); 6.54 (s, 1H); 7.00-7.68 (m, 
3H); 12.77 (s, 1H); 13.97 (bs, 1H); MS m/z 481 (M H+). 
8-[3-(5-Chloro-1H-benzoimidazol-2-ylmethoxy)-1-methyl-1H-pyrazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (52). 
Purification by crystallization from dioxane/Et2O. Yield: 52%, mp: 285-
286°C. 
1H NMR (DMSO-d6): δ 0.88 (m, 6H); 1.57 (q, 2H); 1.73 (q, 2H); 3.86 (t, 
2H); 4.01 (t, 2H); 4.12 (s, 3H); 5.38 (s, 2H); 6.53 (s, 1H); 7.21-7.67 (m, 
3H); 12.92 (s, 1H); 13.97 (bs, 1H).  
8-[3-(5-Methoxy-1H-benzoimidazol-2-ylmethoxy)-1-methyl-1H-pyrazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (53). 
Purification by crystallization from dioxane/water. Yield: 55%, mp: 271-
272°C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.57 (q, 2H); 1.73 (q, 2H); 3.77 (s, 
3H); 3.86 (t, 2H); 4.00 (t, 2H); 4.10 (s, 3H); 5.31(s, 2H); 6.53 (s, 1H); 6.79-
7.48 (m, 3H); 12.48 (s, 1H); 13.97 (bs, 1H); MS m/z 493 (M H+). 
8-[3-(5-Bromo-1H-benzoimidazol-2-ylmethoxy)-1-methyl-1H-pyrazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (54). 
Purification by crystallization from dioxane/water. Yield: 52%, mp: 299 °C 
1H NMR (DMSO-d6): δ 0.88 (m, 6H); 1.58 (q, 2H); 1.75 (q, 2H); 3.85 (t, 
2H); 4.00 (t, 2H); 4.09 (s, 3H); 5.37(s, 2H); 6.66 (s, 1H); 7.22-7.80 (m, 3H); 
12.95 (bs, 1H); 12.99 (bs, 1H); MS m/z 542 (M H+). 
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8-[1-Methyl-3-(5-trifluoromethyl-1H-benzoimidazol-2-ylmethoxy)-1H-
pyrazol-5-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (55). 
Purification by column chromatography on silical gel (AcOEt). Yield: 50%, 
mp: 301 °C. 
1H NMR (DMSO-d6): δ 0.86 (m, 6H); 1.57 (q, 2H); 1.71 (q, 2H); 3.82 (t, 
2H); 3.89(t, 2H); 4.09 (s, 3H); 5.44(s, 2H); 6.55 (s, 1H); 7.50-8.00 (m, 3H); 
13.01 (bs, 1H); 13.99 (bs, 1H); MS m/z 531 (M H+). 
8-[1-Methyl-3-(5-methyl-1H-benzoimidazol-2-ylmethoxy)-1H-pyrazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (56). 
Purification by column chromatography on silical gel (AcOEt). Yield: 86%, 
mp: 276 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.57 (q, 2H); 1.73 (q, 2H); 2.4 (s, 
3H); 3.86 (t, 2H); 4.00(t, 2H); 4.10 (s, 3H); 5.33(s, 2H); 6.48 (s, 1H); 6.93-
7.49 (m, 3H); 12.5 (bs, 1H); 13.96 (bs, 1H); MS m/z 477 (M H+). 
8-[1-Methyl-3-(1H-naphtho[2,3-d]imidazol-2-ylmethoxy)-1H-pyrazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (57). 
Purification by crystallization from DMF/Et2O. Yield: 85%, mp: 297 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.55 (q, 2H); 1.71 (q, 2H); 3.86 (t, 
2H); 4.00 (t, 2H); 4.14 (s, 3H); 5.47 (s, 2H); 6.58 (s, 1H); 7.37 (m, 2H); 8.02 
(m, 4H); 12.73 (s, 1H); 13.98 (bs, 1H); ); MS m/z 513 (M H+). 
8-[3-(5-Nitro-1H-benzoimidazol-2-ylmethoxy)-1-methyl-1H-pyrazol-5-yl]-
1,3-dipropyl-3,7-dihydro-purine-2,6-dione (58). 
Purification by crystallization from dioxane.  Yield: 48 %, mp: 263 °C. 
1H NMR (DMSO-d6): δ 0.88 (m, 6H); 1.58 (q, 2H); 1.72 (q, 2H); 3.86 (t, 
2H); 3.99 (t, 2H); 4.01 (s, 3H); 5.49(s, 2H); 6.57 (s, 1H); 7.74-8.16 (m, 2H); 
8.47 (s, 1H); 12.95 (bs, 1H); 13.99 (bs, 1H); MS m/z 508 (M H+). 
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2-[5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-
1H-pyrazol-3-yloxymethyl]-1H-benzoimidazole-5-carboxylic acid ethyl 
ester (59). 
Purification by crystallization from methanol. Yield: 60 %, mp > 300 °C. 
1H NMR (DMSO-d6): δ 0.89 (m, 6H); 1.32 (t, 3H);1.62 (q, 2H); 1.78 (q, 
2H); 3.86 (t, 2H); 4.01 (t, 2H); 4.10 (s, 3H); 4.34 (q, 2H); 5.42(s, 2H); 6.53 
(s, 1H); 7.76-8.22 (m, 3H); 13.00 (bd, 1H); 13.99 (bs, 1H); MS m/z 535 (M 
H+). 
2-[5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-
1H-pyrazol-3-yloxymethyl]-1H-benzoimidazole-5-carboxylic acid (60).  
Aqueous NaOH 10% (6 mL) was added to a suspension of the ester 59 (0.15 
mmol) in dioxane (10 mL) and the mixture was heated at 50ºC for 3 hours. 
Most of the solvent was evaporated under vacuum, the remaining aqueous 
mixture cooled to room temperature and HCl 10% was added until an acidic 
pH was reached. The resulting precipitate was collected by filtration, 
washed with water and dried to yield the corresponding carboxylic acid 60, 
that was purified by crystallization (dioxane). Yield: 55 %, mp: > 300 °C. 
1H NMR (DMSO-d6): δ 0.89 (m, 6H);1.66 (q, 2H); 1.77 (q, 2H); 4.01 (t, 
2H); 4.05 (t, 2H); 4.10 (s, 3H); 5.41 (s, 2H); 6.66 (s, 1H); 7.67-8.24 (m, 
3H); 12.99 (bs, 1H); 13.00 (bs, 1H); 13.99 (bs, 1H); MS m/z 507 (M H+). 
8-[1-Methyl-3-(4-methyl-1H-benzoimidazol-2-ylmethoxy)-1H-pyrazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (61). 
Purification by column chromatography on silical gel (AcOEt/MeOH 
9.5/0.5). Yield: 86%, mp: 276-277°C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.57 (q, 2H); 1.73 (q, 2H); 2.41 (s, 
3H); 3.86 (t, 2H); 4.00 (t, 2H); 4.12 (s, 3H); 5.33 (s, 2H); 6.48 (s, 1H); 6.93-
7.49 (m, 3H); 12.58 (s, 1H); 13.96 (s, 1H); MS m/z 477 (M H+). 
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8-[3-(4-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-ylmethoxy)-1-
methyl-1H-pyrazol-5-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (62). 
Purification by crystallization from methanol. Yield: 48 %, mp: 267 °C.  
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.59 (q, 2H); 1.78 (q, 2H); 3.83 (t, 
2H); 3.96 (t, 2H); 4.09 (s, 3H); 5.48 (s, 2H); 6.55 (s, 1H); 7.80 (s, 1H); 7.98 
(s, 1H); 13.50 (bs, 1H); 14.00 (bs, 1H); MS m/z 566 (M H+). 
8-[3-(4,6-Bis-trifluoromethyl-1H-benzoimidazol-2-ylmethoxy)-1-methyl-
1H-pyrazol-5-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (63). 
Purification by crystallization from methanol. Yield: 55 %, mp: 280-281 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.59 (q, 2H); 1.78 (q, 2H); 3.93 (t, 
2H); 4.09 (t, 2H); 4.10 (s, 3H); 5.51 (s, 2H); 6.551 (s, 1H); 7.80 (s, 1H); 
8.20 (s, 1H); 13.55 (bs, 1H); 14.00 (bs, 1H); MS m/z 599 (M H+). 
8-[3-(5-Chloro-6-fluoro-1H-benzoimidazol-2-ylmethoxy)-1-methyl-1H-
pyrazol-5-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (64). 
Purification by crystallization from dioxane. Yield: 55 %, mp: 288 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.55 (q, 2H); 1.78 (q, 2H); 3.84 (t, 
2H); 3.99 (t, 2H); 4.07 (s, 3H); 5.35 (s, 2H); 6.50 (s, 1H); 7.50-7.88 (m, 
2H); 13.00 (bd, 1H); 14.00 (bs, 1H); ); MS m/z 516 (M H+). 
8-[3-(5,6-Dimethyl-1H-benzoimidazol-2-ylmethoxy)-1-methyl-1H-pyrazol-
5-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (65). 
Purification by crystallization from methanol. Yield: 75 %, mp: 281 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.55 (q, 2H); 1.70 (q, 2H); 2.29 (s, 
6H); 3.84 (t, 2H); 4.00 (t, 2H); 4.10 (s, 3H); 5.31 (s, 2H); 6.53 (s, 1H); 7.30 
(s, 2H); 12.45 (bs, 1H); 14.00 (bs, 1H); MS m/z 491 (M H+). 
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8-[3-(1H-Benzoimidazol-2-ylmethoxy)-isoxazol-5-yl]-1,3-dipropyl-3,7-
dihydro-purine-2,6-dione (69). 
Purification by crystallization from methanol. Yield: 70 %, mp: 282 °C. 
1H NMR (DMSO-d6): δ 0.88 (m, 6H); 1.58 (q, 2H); 1.80 (q, 2H); 3.98 (t, 
2H); 4.10 (t, 2H); 5.53 (s, 2H); 6.97 (s, 1H); 7.00-7.59 (m, 4H); 12.76 (bs, 
1H); 14.59 (bs, 1H); MS m/z 450 (M H+). 
8-[3-(5-Chloro-1H-benzoimidazol-2-ylmethoxy)-isoxazol-5-yl]-1,3-
dipropyl-3,7-dihydro-purine-2,6-dione (70). 
Purification by crystallization from methanol. Yield: 68 %, mp: 260 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.55 (q, 2H); 1.70 (q, 2H); 3.86 (t, 
2H); 3.94 (t, 2H); 5.54 (s, 2H); 6.99 (s, 1H); 7.20-7.77 (m, 3H); 13.00 (bs, 
1H); 14.55 (bs, 1H); MS m/z 476 (M H+). 
8-[3-(5-Bromo-1H-benzoimidazol-2-ylmethoxy)-isoxazol-5-yl]-1,3-
dipropyl-3,7-dihydro-purine-2,6-dione (71). 
Purification by crystallization from methanol. Yield: 70 %, mp: 230 °C 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.58 (q, 2H); 1.72(q, 2H); 3.89 (t, 
2H); 3.98 (t, 2H); 5.54 (s, 2H); 6.98 (s, 1H); 7.36-7.80 (m, 3H); 13.00 (bs, 
1H); 14.60 (bs, 1H). MS m/z 529 (M H+). 
8-[3-(5-Trifluoromethyl-1H-benzoimidazol-2-ylmethoxy)-isoxazol-5-yl]-
1,3-dipropyl-3,7-dihydro-purine-2,6-dione (72). 
Purification by crystallization from methanol. Yield: 65 %, mp: 268 °C 
1H NMR (DMSO-d6): δ 0.88 (m, 6H); 1.55 (q, 2H); 1.69 (q, 2H); 3.86 (t, 
2H); 3.98 (t, 2H); 5.51 (s, 2H); 7.00 (s, 1H); 7.50-8.00 (m, 3H);  13.20 (bs, 
1H); 14.70 (bs, 1H); MS m/z 518 (M H+). 
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8-[3-(5-Methoxy-1H-benzoimidazol-2-ylmethoxy)-isoxazol-5-yl]-1,3-
dipropyl-3,7-dihydro-purine-2,6-dione (73). 
Purification by crystallization from methanol. Yield: 75%, mp: 199 °C. 
1H NMR (DMSO-d6): δ 0.88 (m, 6H); 1.58 (q, 2H); 1.69 (q, 2H); 3.78 (s, 
3H); 3.86 (t, 2H); 3.98 (t, 2H); 5.48 (s, 2H); 6.86 (s, 1H); 6.97-7.46 (m, 3H); 
13.01 (bs, 1H); 14.30 (bs, 1H); MS m/z 480 (M H+). 
8-[3-(5-Chloro-6-fluoro-1H-benzoimidazol-2-ylmethoxy)-isoxazol-5-yl]-
1,3-dipropyl-3,7-dihydro-purine-2,6-dione (74). 
Purification by crystallization from methanol. Yield: 55 %, mp: 249 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.62 (q, 2H); 1.69 (q, 2H); 3.86 (t, 
2H); 3.97 (t, 2H); 5.54 (s, 2H); 6.98 (s, 1H); 7.50-7.88 (m, 2H); 13.06 (bs, 
1H); 14.61(bs, 1H); MS m/z 502 (M H+). 
8-[3-(4-Chloro-6-trifluoromethyl-1H-benzoimidazol-2-ylmethoxy)-
isoxazol-5-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (75). 
Purification by crystallization from methanol. Yield: 50%, mp: 251 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.59 (q, 2H); 1.69 (q, 2H); 3.86 (t, 
2H); 3.97 (t, 2H); 5.96 (s, 2H); 6.95 (s, 1H); 7.48 (s, 1H); 7.98 (s, 1H); 
12.99 (bs, 1H); 14.60(bs, 1H); MS m/z 552 (M H+). 
8-[3-(4,6-Bis-trifluoromethyl-1H-benzoimidazol-2-ylmethoxy)-isoxazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (76). 
Purification by crystallization from methanol. Yield: 60%, mp: 233 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.52 (q, 2H); 1.56 (q, 2H); 3.86 (t, 
2H); 3.94 (t, 2H); 5.64 (s, 2H); 6.68 (s, 1H); 7.84 (s, 1H); 8.26 (s, 1H); 
13.06 (bs, 1H); 14.00(bs, 1H). MS m/z 586 (M H+).  
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8-[1-Methyl-3-(4-oxo-1,4-dihydro-quinazolin-2-ylmethoxy)-1H-pyrazol-5-
yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (49). 
To a solution of 46 (100 mg, 0.25 mmol) and EDC (60 mg, 0.30 mmol) in 
DMF (5 mL), was added 2-aminobenzamide (35 mg, 0.25 mmol). The reac-
tion mixture was stirred at room temperature for 2h. The solvent was evapo-
rated under vacuo and the residue poured in water. The amidic intermediate 
was filtered and reacted with NaOH (2.5 N, 6 mL) at 80 °C for 2h. After 
cooling to 0 °C, the reaction was acidified to pH 2–3, the resultant solid was 
filtered, and washed with water. The titled compound was purified by flash 
chromatography (ethyl acetate/methanol 9/1). Yield: 60%, mp: > 300 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.56 (q, 2H); 1.72 (q, 2H); 3.85 (t, 
2H); 4.03 (t, 2H); 4.07 (s, 3H); 5.08 (s, 2H); 6.50 (s, 1H); 7.52-8.14 (m, 
4H);12.55 (s, 1H), 13.88 (s, 1H); MS m/z 491 (M H+). 
8-[1-Methyl-3-(7H-purin-8-ylmethoxy)-1H-pyrazol-5-yl]-1,3-dipropyl-3,7-
dihydro-purine-2,6-dione (66). 
The same procedure as reported for the preparation of compounds 50-65, 
expect the temperature of 100 °C necessary for the ring closure of the amide 
intermediate. 
Purification by crystallization from DMF/water. Yield: 60%, mp: 293-
294°C. 
1H NMR (DMSO-d6): δ 0.84 (m, 6H); 1.54 (q, 2H); 1.70 (q, 2H); 3.83 (t, 
2H); 3.97 (t, 2H); 4.05 (s, 3H); 5.44 (s, 2H); 6.50 (s, 1H); 8.87 (s, 1H); 9.03 
(s, 1H); 13.77 (bs, 2H); MS m/z 465 (M H+). 
Methyl 3-(benzyloxy)-1-methyl-1H-pyrazole-5-carboxylate (78). 
K2CO3 (15 mmol) was added to a solution of the methyl 3-hydroxy-1-
methyl-1H-pyrazole-5-carboxylate 77 (2g, 12 mmol) in anhydrous acetone 
(100 mL) at 0°C and the mixture was stirred for 30 min. Benzyl bromide 
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(1.8 mL 15 mmol) was added and the mixture was stirred for 20 h at room 
temperature. The solvent was evaporated, the residue taken up with water 
and the solution was extracted with AcOEt. The organic phase was dried 
over Na2SO4 and evaporated to give an oil compound that was used in the 
next reaction without purification. Yield 85%. 
1H NMR (DMSO-d6): δ 3.93 (s, 3H); 4.10 (s. 3H); 5.13 (s, 2H); 6.25 (s, 
1H); 7.36-7,43 (m, 5H). 
3-(Benzyloxy)-1-methyl-1H-pyrazole-5-carboxylic acid (79). 
Aqueous KOH 2N (10 mL) was added to a suspension of the ester 78 (2 g, 
8.1 mmol) in dioxane (30 mL) and the mixture was stirred at room tempera-
ture for 6 hours. Most of the solvent was evaporated under vacuum, the re-
maining aqueous mixture cooled to room temperature and HCl 10% was 
added until an acidic pH was reached. The resulting precipitate was col-
lected by filtration, washed with water and dried to yield the corresponding 
carboxylic acid 79, that was purified by crystallization (ethanol: water). 
Yield: 98%, mp: 137-138 °C. 
1H NMR (DMSO-d6): δ 3.93 (s, 3H); 5.13 (s, 2H); 6.25 (s, 1H); 7.36-7.43 
(m, 5H); 13.20 (s, 1H). 
8-(3-Benzyloxy-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro-
purine-2,6-dione (80). 
To a mixture of the 3-(benzyloxy)-1-methyl-1H-pyrazole-5-carboxylic acid 
79 (700 mg, 3.0 mmol), EDC (560 mg, 3.0 mmol), and methanol  (20 mL) 
was added 5,6-diamino-1,3-dipropyl-1,3-dihydropyrimidine-2,4-dione (680 
mg, 3.0 mmol)   and the mixture was stirred at room temperature overnight 
under argon atmosphere. The resulting solution was evaporated under re-
duced pressure, and the residue was dissolved in NaOH 2 N (10 mL) and 
heated at 80 °C for 2 hours. After cooling to 0 °C, the reaction was acidified 
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to pH 2–3, the resultant solid was filtered, and washed with water. The titled 
compound was purified by crystallization from DMF. Yield: 65%, mp: 257-
258 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.56 (q, 2H); 1.73 (q, 2H); 3.86 (t, 
2H); 4.00 (t, 2H); 4.08 (s, 3H); 5.16 (s, 2H); 6.48 (s, 1H); 7.37-7.46 (m, 
5H); 13.97 (s, 1H). 
8-(3-Benzyloxy-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-7-(2-
trimethylsilanyl-ethoxymethyl)-3,7-dihydro-purine-2,6-dione (81). 
A mixture of 80 (600 mg, 1.42 mmol), potassium carbonate (1.0 g, 7.1 
mmol) in DMF (20 mL) with SEM-Cl (0.5 mL, 2.84 mmol) was stirred at 
70 °C for 72 h. After concentration under vacuum, the residue was extracted 
with ethyl acetate and washed with brine. The organic layer was dried on 
Na2SO4 and evaporated to afford the N-7 SEM protected 81 as an oil. Yield: 
90%. 
1H NMR (CDCl3): δ 0.017 (s, 9H); 0.95 (m, 6H); 1.65 (m, 2H); 1.83 (m, 
4H); 3.76 (t, 2H); 3.99 (t, 2H); 4.02 (s, 3H); 4.11 (t, 2H); 5.23 (s, 2H); 5.72 
(s, 2H); 6.45 (s, 1H); 7.37-7.45 (m, 5H).   
8-(3-Hydroxy-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-7-(2-
trimethylsilanyl-ethoxymethyl)-3,7-dihydro-purine-2,6-dione (82). 
The N-7-SEM protected 81 (600 mg, 1.08 mmol), palladium on carbon 
(10%, 600 mg), and ammonium formate (340 mg, 5.4 mmol) in methanol 
(100 mL) was refluxed for 6 h. The resultant suspension was filtered 
through Celite, washed with methanol to afford 82 after concentration under 
vacuum. The solid was purified by crystallization from Et2O. Yield: 95%, 
mp: 170-171 °C.  
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1H NMR (DMSO-d6): δ 0.095 (s, 9H); 0.86 (m, 6H); 1.58 (q, 2H); 1.72 (q, 
2H); 3.64 (t, 2H); 3.83 (s, 3H); 3.86 (t, 2H); 4.01 (t, 2H); 5.67 (s, 2H); 6.16 
(s, 1H); 10.20 (bs, 1H). 
8-{3-[5-(3-Methoxy-phenyl)-[1,2,4]oxadiazol-3-ylmethoxy]-1-methyl-1H-
pyrazol-5-yl}-1,3-dipropyl-7-(2-trimethylsilanyl-ethoxymethyl)-3,7-
dihydro-purine-2,6-dione (84). 
The hydroxyl pyrazolo 82 (50 mg, 0.1 mmol) and potassium carbonate (40 
mg, 0.3 mmol) in anhydrous acetone (10 mL) was reacted with 5-[(3-
methoxy)phenyl]-3-chloromethyl-1,2,4-oxadiazole 83 (0.1 mmol) at 60 °C 
for 24 h. The mixture was cooled, diluted with water and extracted with 
AcOEt. The organic layer was dried over Na2SO4 and evaporated under 
vacuum to give a solid residue that was purified by column chromatography 
on silica gel (ethyl acetate–hexane 2/8) to afford 82. Yield 98%, mp: 68-69 
°C. 
1H NMR (DMSO-d6): δ 0.10 (s, 9H); 0.85 (m, 10H); 1.59 (q, 2H); 1.74 (q, 
2H); 3.62 (t, 2H); 3.86 (s, 3H); 3.88 (s, 3H); 4.02 (t, 2H); 5.43 (s, 2H); 5.70 
(s, 2H); 6.46 (s, 1H); 7.24-7.78 (m, 4H). 
8-{3-[5-(3-Methoxy-phenyl)-[1,2,4]oxadiazol-3-ylmethoxy]-1-methyl-1H-
pyrazol-5-yl}-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (85). 
The SEM protected 84 (50 mg, 0.07 mmol) was dissolved in ethanol (2 mL) 
and treated with HCl 1N (0.5 ml) for 4 h at 85 °C. After cooling to room 
temperature, the solid obtained was filtered, washed with ethanol to afford 
pure 85. Yield: 85 %, mp: 242 °C.  
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.55 (q, 2H); 1.73 (q, 2H); 3.87 (s, 
3H); 3.89 (t, 2H); 4.01 (t, 2H); 4.09 (s, 3H); 5.40 (s, 2H); 6.53 (s, 1H); 7.31-
7.74 (m, 4H); 13.98 (s, 1H); MS m/z 521 (M H+). 
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8-(3-Hydroxy-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro-purine-
2,6-dione (86). 
The same procedure as reported for the preparation of compound 82, expect 
used 80. Yield: 80%, mp: > 300 °C. 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.55 (q, 2H); 1.75 (q, 2H); 3.86 (t, 
2H); 3.89 (t, 2H); 4.04 (s, 3H); 6.25 (s, 1H); 9.95 (s, 1H); 13.80 (bs, 1H); 
MS m/z 333 (M H+). 
3-Benzyloxy-1-methyl-1H-pyrazole-5-carbaldehyde (87). 
Ethyl chloroformate (2 mmol) was added at -10 °C to a solution of 5-
pyrazole carboxylic acid 87 (440 mg, 1.9 mmol), anhydrous tetrahydrofu-
rane (THF) (15 mL), and triethylamine (0.2 mL, 2 mmol). After stirring for 
30 min at 0°C the white precipitate was filtered and washed with THF The 
filtrate was added slowly to a suspension of NaBH4 (5 mmol) in water (5 
mL ) at 0°C. The stirring was continued for 1 h at room temperature. The 
resultant suspension was acidified with HCl 5N and extracted with ethyl 
acetate. The organic layer was dried (Na2SO4) and evaporated to afford the 
corresponding alcohol as an oil that used for the next step without further 
purification. The alcohol (400 mg. 1.8 mmol) was dissolved  in CH2Cl2 
(5mL) and added  dropwise to a suspension of pyridinium chlorochromate 
(5.5 mmol in 10 mL CH2Cl2) under gentle stirring. The reaction mixture was 
allowed at room temperature for 20 minutes. The solvent layer was decanted  
from the black residue, and rinsed the residue twice with about 5 mL of 
methylene chloride. Evaporated the combined methylene chloride solutions 
on a rotary evaporator. The residual material was diluted with 50 mL of 
diethyl ether and filter through cotton plug to remove the insoluble 
chromium salts. The ether layer was dried with anhydrous Na2SO4. The sol-
vent was evaporated in vacuo and the residue was purified by flash chro-
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matography (ethyl acetate–hexane 2/8) to afford aldehyde 88 as a colorless 
oil. Yield 85%. 
1H NMR (CDCl3-d): δ  -4.04 (s, 3H); 5.21 (s, 2H); 6.24 (s, 1H); 7.35-7.43 
(m, 5H); 9.73 (s, 1H).  
6-[2-(3-Benzyloxy-1-methyl-1H-pyrazol-5-yl)-vinyl]-5-nitro-1,3-dipropyl-
1H-pyrimidine-2,4-dione (90). 
A solution of 6-methyl-5-nitro-1,3-dipropyl-1H-pyrimidine-2,4-dione 89 
(200 mg, 0.78 mmol), morpholine (0.07 mL, 0.86 mmol), and p-
toluensulphonic acid  (catalytic amount) in dry toluene (5 mL) was refluxed 
for 2 h, under argon atmosphere. The pyrazolo aldehyde 88 (168 mg, 0.78 
mmol) was added, the reaction mixture was allowed at reflux overnight. The 
resulting solution was diluted with ethyl acetate, and washed with HCl 5 % 
and brine. The solvent was dried with anhydrous Na2SO4 and evaporated in 
vacuum; the residue was purified by crystallization. (diethyl ether–hexane) 
to yield the expected nitrostyryl derivatives 90 as a pale yellow solid. Yield 
65%; mp: 120-121 °C. 
1H NMR (DMSO-d6): δ 0.85 (m, 6H); 1.58 (m, 4H); 3.66 (s, 3H); 3.81 (m, 
4H); 5.13 (s, 2H); 6.36 (s, 1H); 6.98 (d, 1H, J = 16.1 Hz); 7.05 (d, 1H, J = 
16.1 Hz); 7.38 (m, 5H). 
6-(3-Benzyloxy-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-1,5-dihydro-
pyrrolo[3,2-d]pyrimidine-2,4-dione (91). 
To a solution of 5-nitro-6-styryluracil 90 (100 mg, 0.22 mmol) in ethanol (4 
mL), and acetic acid 20% (0.8 mL) was added iron (160 mg), and the mix-
ture was refluxed overnight. The resulting suspension was cooled to room 
temperature. After concentration under vacuum, residual material was di-
luted with 50 mL of ethyl acetate and 30 mL water and filtered through 
Celite. The organic layer was separated, washed with brine, and dried with 
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anhydrous Na2SO4. The solvent was evaporated in vacuum and the residue 
was purified by crystallization (diethyl ether / hexane) to yield the expected. 
1H-pyrrolo[3,2-d]-pyrimidine-2,4(3H,5H)-dione 91 as a white solid. Yield 
92%; mp: 158-159 °C 
1H NMR (DMSO-d6): δ 0.95 (m, 6H); 1.66 (q, 2H); 1.81 (q, 2H); 3.90 (s, 
3H); 4.01(m, 4H); 5.23 (s, 2H); 6.04 (s, 1H); 6.07 (s, 1H)); 7.43 (m, 5H); 
11.02 (bs, 1H). 
6-(3-Hydroxy-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-1,5-dihydro-
pyrrolo[3,2-d]pyrimidine-2,4-dione (92). 
Same procedure as for compound 82 expect used 91. Yield 80 %; mp: 282°C 
1H NMR (DMSO-d6): δ 0.87 (m, 6H); 1.62 (m, 2H); 3.76 (s, 3H); 3.85 (m, 
4H); 5.96 (s, 2H); 6.51 (s, 1H); 9.77 (bs, 1H); 12.3 (bs, 1H); MS m/z 332 (M 
H+). 
(5-Formyl-1-methyl-1H-pyrazol-3-yloxy)-acetic acid ethyl ester (94). 
The same procedure as for compound 88 except used 93. Colourless oil, 
yield: 85% 
1H NMR (CDCl3-d): δ 1.29 (t, 3H); 4.00 (s, 3H); 4.28 (q, 2H); 4.77(s, 2H); 
6.30 (s, 1H); 9.73 (s, 1H). 
{1-Methyl-5-[2-(5-nitro-2,6-dioxo-1,3-dipropyl-1,2,3,6-tetrahydro-
pyrimidin-4-yl)-vinyl]-1H-pyrazol-3-yloxy}-acetic acid ethyl ester (95). 
The same procedure as for compound 90 except used 94.  
Yellow oil, yield: 55% 
1H NMR (CDCl3-d): δ 0.97 (m, 6H); 1.29 (t, 3H); 1.69 (m, 4H); 3.70 (s, 
3H); 3.94 (m, 4H); 4.28 (q, 2H); 4.75 (s, 2H); 5.99 (s, 1H); 6.45 (d, 1H, J = 
16.2 Hz); 6.87 (d, 1H, J = 16.2 Hz). 
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[5-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]-
pyrimidin-6-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetic acid ethyl ester (96). 
The same procedure as for compound 91 except used 95. Yield: 60%, mp: 
186-187 °C. 
1H NMR (DMSO-d6): δ 0.90 (m, 6H); 1.17 (t, 3H); 1.71 (m, 4H); 3.81 (s, 
3H); 3.87 (m, 4H); 4.15 (q, 2H); 4.74 (s, 2H); 6.19 (s, 1H); 6.56 (s, 1H); 
12.38 (bs, 1H). 
[5-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-
6-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetic acid (97). 
Pyrazolo ethyl estere 96 (300 mg, 0.71 mmol) was dissolved in a  solution 
of aqueous NaOH 1 N (4 mL) and methanol (10 mL), followed by stirring at 
room temperature for 2 h. Water (15 mL) and a 1N aqueous solution of HCl 
was added to the mixture up to an acidic pH to afford 97 as a white crude 
precipitate that was filtered, dried and used for the next step without further 
purification. Yield : 77%, mp: 223-224 °C. 
1H NMR (DMSO-d6): δ 0.86 (m, 6H); 1.62 (m, 4H); 3.81 (s, 3H); 3.86 (m, 
4H);4.63 (s, 2H); 6.18 (s, 1H); 6.57 (s, 1H); 12.43 (bs, 1H); 13.00 (bs, 1H). 
6-[3-(1H-Benzoimidazol-2-ylmethoxy)-1-methyl-1H-pyrazol-5-yl]-1,3-
dipropyl-1,5-dihydro-pyrrolo[3,2-d]pyrimidine-2,4-dione (98). 
The same procedure as for compound 50 except used 97. Yield: 85%, mp: 
224°C. 
1H NMR (DMSO-d6): δ 0.86 (m, 6H); 1.75 (m, 4H); 3.86 (s, 3H); 3.99 (m, 
4H); 5.34 (s, 2H); 6.26 (s, 1H); 6.55 (s, 1H); 7.20-7.62 (m, 4H); 12.50 (bs, 
1H); 12.65 (bs, 1H); MS m/z 462 (M H+). 
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Preparation of 2-[5-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-
pyrrolo[3,2-d]pyrimidin-6-yl)-1-methyl-1H-pyrazol-3-yloxy]-N-(4-fluoro-
phenyl)-acetamide (99) and N-Benzo[1,3]dioxol-5-yl-2-[5-(2,4-dioxo-1,3-
dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)-1-methyl-
1H-pyrazol-3-yloxy]-acetamide (100). 
To a mixture of the carboxylic acid 97 (0.15 mmol), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.15 mmol), 
and anhydrous DMF (5 mL) was added the appropriate aniline (0.15 mmol) 
and the mixture was stirred at room temperature 5 hours under argon atmos-
phere. The resulting solution was evaporated under reduced pressure, and at 
the residue was added water and the precipitate was collected by filtration 
and washed with water . The resulting crude was purified by flash column 
chromatography on silica gel (AcOEt-methanol 9/1). Yield: 65%. 
99: mp: 215 °C. 1H NMR (DMSO-d6): δ 0.86 (m, 6H); 1.62 (m, 4H); 3.82 
(s, 3H); 3.86 (m, 4H);4.73 (s, 2H); 6.24 (s, 1H); 6.57 (s, 1H); 7.15 (m, 2H); 
7.62 (m, 2H); 10.15 (bs, 1H); 12.40 (bs, 1H); MS m/z 483 (M H+). 
100: mp: 226 °C. 1H NMR (DMSO-d6): δ 0.86 (m, 6H); 1.62 (m, 4H); 3.82 
(s, 3H); 3.86 (m, 4H);4.70 (s, 2H); 5.98 (s, 2H);  6.23 (s, 1H); 6.56 (s, 1H); 
6.83-7.02 (m, 2H); 7.32 (s, 1H); 9.99 (bs, 1H); 12.44 (bs, 1H), MS m/z 509 
(M H+). 
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Determination of affinity (Ki) and potency (IC50) values of the novel ad-
enosine compounds. 
Biological Esperiments were performed by Prof. Borea et al., Dipartimento 
di Medicina Clinica e Sperimentale-Sezione di Farmacologia, Università di 
Ferrara. 
Cell membranes preparation. 
The human adenosine receptors have been transfected in CHO or HEK293 
cells according with the method previously described.105,106 Briefly, the cells 
were grown adherently and maintained in Dulbecco's Modified Eagles Me-
dium with nutrient mixture F12 (DMEM/F12) without nucleosides, contain-
ing 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 µg/ml), 
L-glutamine (2 mM) and Geneticin (G418, 0,2 mg/ml) at 37°C in 5% 
CO2/95% air. For membrane preparation the culture medium was removed 
and the cells were washed with phosphate-buffered saline and scraped off 
T75 flasks in ice-cold hypo tonic buffer (5 mM Tris HCl, 1 mM EDTA, pH 
7.4). The cell suspension was homogenized with Polytron, the homogenate 
was spun for 10 min at 1000 x g and the supernatant was then centrifuged 
for 30 min at 100,000 x g. The membrane pellet was suspended in 50 mM 
Tris HCl buffer (pH 7.4) for A1 adenosine receptors, in 50 mM Tris HCl, 10 
mM MgCl2 (pH 7.4) for A2A adenosine receptors, in  50 mM Tris HCl, 10 
mM MgCl2, 1 mM EDTA (pH 7.4) for A2B and A3 adenosine receptors.   
Human cloned A1, A2A, A2B and A3 Adenosine Receptor Binding Assay.  
All new synthesized compounds have been tested to evaluate their affinity 
to human A1, A2A, A2B and A3 adenosine receptors. Displacement experi-
ments of [3H]-DPCPX to CHO cells transfected with the human recombi-
nant A1 adenosine receptors were carried out for 120 min at 25°C incubating 
diluted membranes (50 µg of protein/assay) and at least 6-8 different con-
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centrations of examined antagonists.107 Non specific binding was deter-
mined in the presence of DPCPX 10 µM and this was always ≤ 10% of the 
total binding. Binding of [3H]-ZM 241385 to CHO cells transfected with the 
human recombinant A2A adenosine receptors was performed by using a sus-
pension of membranes (50 µg of protein/assay) and at least 6-8 different 
concentrations of studied antagonists for an  incubation time of 60 min at 
4°C.108 Non specific binding was determined in the presence of 1 µM ZM 
241385 and was about 20% of total binding. Competition binding experi-
ments of [3H]-MRE 2029F20 to HEK293 cells transfected with the human 
recombinant A2B adenosine receptors were carried out incubating  for 120 
min at 4°C diluted membranes (50 µg of protein/assay) and at least 6-8 dif-
ferent concentrations of examined compounds.109 Non-specific binding was 
defined as binding in the presence of 1 µM MRE 3029F20 and was about 
25% of total binding. Inhibition binding assays of [3H]-MRE 3008F20 in 
CHO cells transfected with the human recombinant A3 adenosine receptors 
were performed incubating  for 120 min at 4°C diluted membranes (50 µg 
of protein/assay) and at least 6-8 different concentrations of examined lig-
ands.69 Non-specific binding was defined as binding in the presence of 1 µM 
MRE 3008F20 and was about 25% of total binding. Bound and free radioac-
tivity were separated by filtering the assay mixture through Whatman GF/B 
glass fiber filters using a Micro-Mate 196 cell harvester (Packard Instrument 
Co.). The filter bound radioactivity was counted on a Top Count (efficiency 
57%) with Micro-Scint 20. 
Measurement of cyclic AMP levels in CHO cells transfected with human 
A2B adenosine receptors.  
CHO cells transfected with human A2B adenosine receptors were washed 
with phosphate-buffered saline, diluted tripsine and centrifuged for 10 min 
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at 200 g. The pellet containing the CHO cells (1x106 cells /assay) was sus-
pended in 0.5 ml of incubation mixture: NaCl 150 mM, KCl 2.7 mM, 
NaH2PO4 0.37 mM, MgSO4 1 mM, CaCl2 1 mM, Hepes 5 mM, MgCl2 10 
mM, glucose 5 mM, pH 7.4 at 37°C. Then 2.0 IU/ml adenosine deaminase 
and 0.5 mM 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 20-
1724) as phosphodiesterase inhibitor were added and preincubated for 10 
min in a shaking bath at 37°C (6- Varani et al., 2005). The potencies of an-
tagonists studied were determined by antagonism of NECA (100 nM)-
induced stimulation of cyclic AMP levels. The reaction was terminated by 
the addition of cold 6% thrichloroacetic acid (TCA). The TCA suspension 
was centrifuged at 2000 g for 10 min at 4°C and the supernatant was ex-
tracted four times with water saturated diethyl ether. The final aqueous solu-
tion was tested for cyclic AMP levels by a competition protein binding as-
say. Samples of cyclic AMP standard (0-10 pmoles) were added to each test 
tube containing the incubation buffer (trizma base 0.1 M, aminophylline 8.0 
mM, 2 mercaptoethanol 6.0 mM, pH 7.4) and [3H] cyclic AMP in a total 
volume of 0.5 ml. The binding protein previously prepared from beef adre-
nals, was added to the samples previously incubated at 4°C for 150 min, and 
after the addition of charcoal were centrifuged at 2000 g for 10 min. The 
clear supernatant was counted with 4 ml of Atomlight liquid scintillator and 
counted in a Tri Carb Packard 2500 TR scintillation counter. 
Data Analysis. The protein concentration was determined according to a 
Bio-Rad method110 with bovine albumin as a standard reference. Inhibitory 
binding constant, Ki, values were calculated from those of IC50 according to 
Cheng and Prusoff equation Ki = IC50/(1+[C*]/KD*), where [C*] is the con-
centration of the radioligand and KD* its dissociation constant.111 In addi-
tion, a weighted non linear least-squares curve fitting program LIGAND 
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was used for computer analysis of the inhibition binding experiments.112 The 
IC50 values obtained in cyclic AMP assays were calculated by nonlinear 
regression analysis using the equation for a sigmoidal concentration re-
sponse curves (Graph Pad Prism, San Diego, USA). All experimental data 
are expressed as the geometric mean with 95% confidence limits in paren-
theses of three or four independent experiments performed in duplicate. 
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It has been a pleasure and I have learned much from my short time in his 
lab. I’m greatly appreciative for the time and guidance that Professor Boger 
provided me and for giving me the chance to be a part of his group. 
 
 
 
 
 
 
 
 
 
 
 
 
Reasearch group of Professor Boger, 2007-2008 
During my stage as External Graduate Student, I’ve completely changed the 
field of my research. I was involved in their Inhibitors of Fatty Acid Amide 
Hydrolase (FAAH) Project. My work included the scale up synthesis of key 
α-ketoheterocycle inhibitors of FAAH for in vivo analysis. 
For patent and publication reasons I’m not able to present the experimental 
section about the compound that were investigated. 
I will report in the following chapter a short overview on the research aim I 
have performed at TSRI. 
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Inhibitors of Fatty acid Amide Hydrolase
The medicinal use of cannabis dates back to early recorded history. As early 
as 2600 B.C., ancient Chinese texts record the use of cannabis for the relief 
of numerous conditions including rheumatic and menstrual pain.1 Modern 
scientific investigations into the biological mechanisms surrounding the
effects of cannabis have resulted in the discovery of its principle active 
components cannabidiol and 9-tetrahydrocannabinol (THC),2,3 as well as 
the receptors at which they act (CB1 and CB2).4,5 More recently in the USA,
cannabis-derived extracts or synthetic CB1 agonists have been approved by 
regulatory agencies for refractory chemotherapy-induced nausea and vomit-
ing (nabilone, dronabinol), appetite stimulation in AIDS patients (dronabi-
nol), neuropathic pain of multiple sclerosis, and adjunctive treatment of 
advanced cancer pain (Sativex). 
However, a major limitation to the utility of direct cannabinoid agonists as 
therapeutic agents is the undesirable profile of side effects, which includes
dysphoria, dizziness, and effects on motor coordination and memory. In 
particular, the cognitive effects of these agents appear to be sufficiently 
aversive to markedly limit their use.6,7
Figure 6. Leaves of a Cannabis plant.
The discovery of the CB1 and CB2 
receptors instigated a search for 
endogenous agonists of these 
receptors and subsequently the 
enzymes that control their synthesis 
and degradation. Anandamide 
(AEA) was the first endocannabinoid signaling molecule to be recognized 
as such.8 This discovery was followed by the identification of 2-arachidonyl 
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glycerol (2-AG) as a second endocanabinoid.9,10 Today it is recognized that 
a wide variety of fatty acid amide signaling molecules exist, and while their 
historic origin resulted in the term “endocannabinoids”, it is now clear that 
the actions of these signaling lipids are much more diverse. Further investi-
gations revealed that the actions of these signaling lipids are terminated by 
the hydrolytic activity of a number of enzymes.  
Although the existence of an ethanolamide degrading activity was known 
since 1966,11 it was only in 1996 when researchers at Scripps identified fatty 
acid amide hydrolase (FAAH) as the enzyme responsible for rat oleamide 
hydrolysis that the first enzyme degrading these signaling lipids was cloned 
and characterized.12  
Its distribution is consistent with its role in degrading and regulating such 
neuromodulating and signaling fatty acid amides at their sites of action.13 
Although it is a member of the amidase signature family of serine hydro-
lases, for which there are a number of prokaryotic enzymes, it is currently 
the only characterized mammalian enzyme bearing the family’s unusual 
Ser–Ser–Lys catalytic triad.12-18 
One attractive approach to elicit the desirable effects of cannabinoid activa-
tion, while avoiding the negative effects of global CB1 stimulation, is to 
manipulate endogenous cannabinoid signaling through the inhibition of 
FAAH and related enzymes. Resting concentrations of AEA in the CNS are 
very low because of its rapid hydrolysis by FAAH.19,20 In addition, FAAH 
controls the levels of other lipid mediators with anti-inflammatory and anal-
gesic properties, including PEA, which exerts its analgesic and antiinflam-
matory effects via non-cannabinoid pathways. Inhibition of FAAH would 
be expected to elevate the endogenous concentrations of all of its substrates 
and consequently prolong and potentiate their biological effects. 
Inhibitors of Fatty acid Amide Hydrolase

Figure 7. The enzyme regulation of FAAH signaling and its structure determinated 
by X-ray crystallography. Cartoon model showing FAAH-catalyzed hydrolysis of 
anandamide to arachidonic acid, leading to the inactivation of this endocannabinoid 
signaling molecule.
Such potentiation, acting preferentially on active pathways, might be ex-
pected to have a reduced risk of psychotropic effects compared with global 
activation of cannabinoid receptors by exogenously applied agonists. Direct 
evidence for such up regulation of synthesis in a context relevant to noci-
ception was shown by the demonstration that intraplantar injection of for-
malin led to release of AEA selectively in the periaqueductal gray region of 
the brain, which is associated with nociceptive processing.21 Anandamide 
synthesis is also up-regulated following physiological stress, and it has been 
proposed that an increased endocannabinoid tone under stressful physio-
logical situations may represent an endogenous neuroprotective mecha-
nism.22-24
As it is reported below, preliminary evidence suggested that the limited
pharmacological activity of anandamide may be due to its rapid catabolism 
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in vivo, as this lipid is hydrolyzed to arachidonic acid within minutes of 
exogenous administration.25 Nonetheless, the relative contribution made by 
FAAH to the hydrolysis of anandamide in vivo remained unclear until a 
mouse model was generated in which this enzyme was genetically disrupted 
(FAAH knockout (KO) mice).20 Is reported that tissues from these FAAH-
KO mice displayed a 50–100- fold reduction in hydrolysis rates for anan-
damide and related FAAs. In contrast to wild-type mice, in which adminis-
tered anandamide failed to produce significant behavioral effects, FAAH-
KO mice exhibited robust responses to this FAA, becoming hypomotile, 
analgesic, cataleptic and hypothermic. Notably, all of the behavioural ef-
fects of anandamide in FAAH-KO mice were blocked by pre-treatment with 
the CB1 receptor antagonist SR141716A, indicating that anandamide acted 
as a potent and selective CB1 ligand in these animals. Consistent with this 
notion, the apparent binding affinity of anandamide for the CB1 receptor 
increased approximately 15-fold in brain homogenates from FAAH-KO 
mice.26 Neurochemical studies revealed that endogenous levels of anan-
damide and other NAEs were elevated 10–15 fold in several brain regions 
of FAAH-KO mice, including hippocampus, cortex and cerebellum.20,27 In-
terestingly, these augmented central nervous system levels of FAAs corre-
lated with a CB1-dependent reduction in pain sensation in FAAH-KO 
mice.20 Collectively, these findings indicate that FAAH is a key enzyme 
involved in FAA catabolism in vivo and suggest that pain pathways are un-
der the influence of a FAAH-regulated endocannabinoid one.  
Notably, however, FAAH-KO mice exhibited normal motility, body weight 
and body temperature, indicating that several other neurobehaviors affected 
by exogenously applied CB1 agonists were not under tonic control of anad-
amide in these animals. (Table 8) 
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Table 8. A comparison of the behavioral effects produced by CB1 agonists versus 
the genetic (KO) or chemical (inhibitor) inactivation of FAAH. 
 
Due to the therapeutic potential of inhibiting FAAH14,28-30, there has been an 
increasing interest in the development of selective and potent inhibitors of 
the enzyme.27 Early studies shortly following the initial characterization of 
the enzyme led to the discovery that the endogenous sleep-inducing mole-
cule 2-octyl α-bromoacetoacetate is an effective FAAH inhibitor,31 the dis-
closure of a series of nonselective reversible inhibitors bearing an electro-
philic ketone (e.g., trifluoromethyl ketone-based inhibitors),32-35 and the re-
ports of a set of irreversible inhibitors36-41 (e.g., fluorophosphonates and sul-
fonyl fluorides).  To date, only two classes of inhibitors have been disclosed 
that provide opportunities for the development of inhibitors with therapeutic 
potential. One class is the reactive aryl carbamates and ureas42-60 that irre-
versibly acylate a FAAH active site serine39 and that have been shown to 
exhibit anxiolytic activity42 and produce analgesic effects.61 To date and 
Potential therapeutic effects (application) 
 Analgesia 
(pain) 
 
Anxiolysis 
(anxiety) 
 
Anti-spasticity 
(multiple sclerosis) 
 
Anti-emesis 
(nausea) 
 
Decreases 
IOP++ 
(glaucoma) 
CB1 
agonist* Yes Yes/No Yes Yes Yes 
FAAH-KO 
mice 
Yes Unknown 
 
Unknown Unknown No 
FAAH 
inhibitor 
Yes Yes Unknown Unknown No 
Side Effects 
 Hypomotility Hypothermia Catalepsy 
CB1 agonist* Yes Yes Yes 
FAAH-KO mice No No No 
FAAH inhibitor No No No 
Inhibitors of Fatty acid Amide Hydrolase 
 
 84 
with some exceptions, the selectivity of such inhibitors has often been 
low35,46,47,60-64 further complicating the development of inhibitors that irre-
versibly and covalently modify the target enzyme. A second class is the α-
ketoheterocycle-based inhibitors65-73 that bind to FAAH via reversible 
hemiketal formation with an active site serine.  Many of these competitive 
inhibitors are not only potent and extraordinarily selective for FAAH versus 
other mammalian serine hydrolases, but members of this class have been 
shown to be efficacious analgesics in vivo.72,73 
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125I-ABOPX: 125I-3-(3,4-aminobenzyl)-8-(4-oxyacetate)phenyl-1-propyl-xanthine 
ADA: Adenosine Deamnase 
ADP: Adenosine Diphosphate 
AEA: Anandamide 
2-AG: 2-arachidonyl glycerol 
ARs: Adenosine Receptors 
ASMCs: Arterial Smooth Muscle Cells 
ATP: Adenosine Triphosphate 
BALF: bronchoalveolar fluid 
BAY 60-6583: 2-[6-amino-3,5-dicyano-4-(4-hydroxyphenyl)pyridin-2-
ylsulfanyl]acetamide 
cAMP: cyclic Adenosine Monophosphate 
CB: Cannabinoid 
CFTR: Cystic Fibrosis Transmembrane Conductance Regulator 
CGS21680: 2-([4-(2-carboxyethyl)phenylethyl]amino)-5'-N-ethylcarboxamido -
adenosine 
CHO cells: Chinese Hamster Ovary cells 
CNS: Central Nervous System 
COPD: Chronic Obstructive Pulmonary Disease 
DAG: Diacylglycerol 
DMF: Dimethylformamide 
DMSO: Dimethylsulfoxide 
DNA: Deoxyribonucleic acid 
[3H]-DPCPX: [3H]-1,3-dipropyl-8-cyclopentyl-xanthine 
EDC: 1-[3-(dimethyl-amino)-propyl]-3-ethylcarbodiimide hydrochloride 
EDG: Elettron Donating Group 
EWG: Elettron Withdrawing Group 
FAA: Fatty Acid Amide 
FAAH: Fatty Acid Amide Hydrolase 
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FAD: Flavin Adenine Dinucleotide 
GMCs: Glomerular Mesangial Cells  
HEK293 cells: Human Embryonic Kidney cells 
HMC-1: Human Mast Cells-1 
IC50: Inhibitory Concentration(50%) 
IL: Interleukin 
IP3: Inosytoltriphospate 
IPC:  Ischemic Preconditioning  
Ki: Equilibrium inhibition costant 
KO: Knockout 
Lys: Lysine 
MAPK: Mitogen-Activated Protein Kinase  
[3H]-MRE 2029-F20: [3H]-N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-dipropyl-2,6-dioxo-
2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide] 
[3H]-MRS 1754: [3H]-[N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-
dipropyl-1H-purin-8-yl)-phenoxy]acetamide 
MS: Mass Spettrometry 
NAD: Nicotinamide Adenine Dinucleotide 
NECA: 5'-N-ethylcarboxamidoadenosine 
NMR: Nuclear Magnetic Resonance 
NO: Nitric Oxide 
[3H]-OSIP339391: [3H]-N-(2-(2-Phenyl-6-[4-(2,2,3,3-tetratritrio-3-phenylpropyl)-
piperazine-1-carbonyl]-7Hpyrrolo[2,3-d]pyrimidin-4-ylamino)-ethyl)-Acetamide 
PCC: Pyridinium chlorocromate 
PDE: Phosphodiesterase Enzyme 
PEA: Palmitoylethanolamide 
RNA: Ribonucleic acid  
RT: Room Temperature 
SAM: S-Adenosyl-L-Methionine 
SAR: Structure Activity Relationship 
SEM-Cl: 2-(trimethylsilyl)-ethoxymethyl choride 
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Ser: Serine 
TEA: Triethylamine 
THC: Δ9-tetrahydrocannabinol 
THF: Tetrahydrofuran 
TNFα: Tumor Necrosis Factor α 
XAC: Xanthine Amino Congener 
XCC: Xanthine Carboxilic Congener 
[3H]-ZM 241385: [3H]-(4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo-[2,3-
a][1,3,5]triazin-5-ylamino] ethyl)-phenol 
 
